Section 3 of 6
Product information and disease description
434 evidence topics · 165 sources
Product description
Phase of product development
Regulatory status: Under review; NDA accepted July 2026, PDUFA target action date April 2027
Launch: Anticipated in 2027
Investigational status and approval uncertainty
European Medicines Agency marketing authorization application
NDA submission timing, May 2026, superseded in July 2026
NDA submission timing, April 2026, superseded in July 2026
NDA submission timing, January 2026, superseded in July 2026
NDA submission timing, December 2025, superseded in July 2026
NDA submission timing, July 2025, superseded in July 2026
RAPIDe-3 topline timing, January 2025, superseded in July 2025
Development history: duration of the development program
Development history: phase 1 studies and the RAPIDe-1 phase 2 trial
Development history: RAPIDe-3 initiation, enrollment, and topline results
Development history: RAPIDe-2 open-label extension
Development history: CHAPTER-1, CHAPTER-3, and CHAPTER-4 prophylaxis trials of deucrictibant
Development history: CREAATE in acquired angioedema due to C1 inhibitor deficiency
FDA clinical hold, August 2022, and its lifts in June 2023 and January 2024
FDA orphan drug designation
| Field | Quoted record |
|---|---|
| Generic name | “deucrictibant” |
| Date designated | “03/18/2022” |
| Orphan designation | “Treatment of bradykinin-mediated angioedema (hereditary or acquired)” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Pharvaris GmbH” |
Orphan designations in the European Union and Switzerland
| Field | Quoted record |
|---|---|
| Active substance | “deucrictibant monohydrate” |
| Intended use | “Treatment of bradykinin-mediated angioedema” |
| EU designation number | “EU/3/25/3040” |
| Date of designation | “25/03/2025” |
| Sponsor | “Pharvaris Netherlands B.V.” |
EU paediatric investigation plan, agreed October 2023 and modified January 2025
FDA expedited program designations
No evidence found.
Patent protection
Product information
Generic, brand name and therapeutic class of product
Ownership and license of the compound
Nonproprietary name, development codes, and therapeutic class
Brand name
No evidence found.
Dosage forms and strengths
Immediate-release capsule, 20 mg: intended commercial dosage
RAPIDe-3 study drug: one soft capsule per dose
Pharmaceutical forms in the EU paediatric investigation plan
Material safety data sheet
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
WHO International Nonproprietary Name functional class
AHFS classification
No evidence found.
Indication
Indication named in the NDA accepted by the FDA
Age range: adults and adolescents 12 years and older
Indication named in the FDA orphan drug designation
Investigational population in RAPIDe-3, including hereditary angioedema with normal C1 inhibitor
Pharmacology
Mechanism of action
Competitive antagonism of the bradykinin B2 receptor
Potency and selectivity in vitro, ex vivo, and in vivo
In vitro pharmacological profile of deucrictibant and its active metabolite
“The present study describes the in vitro pharmacological characteristics of PHA-022121 and its active metabolite, PHA-022484 (M2-D).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In mammalian cell lines, PHA-022121 and PHA-022484 show high affinity for the recombinant human bradykinin B2 receptor with Ki values of 0.47 and 0.70 nM, respectively, and potent antagonism of the human bradykinin B2 receptor with Kb values of 0.15 and 0.26 nM, respectively (calcium mobilization assay).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“potency at rat, mouse, rabbit and dog bradykinin B2 receptors is at least 100-fold lower than the potency at the human receptor for both compounds.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It is about 20-fold more potent than icatibant at the human bradykinin B2 receptor as assessed using recombinant or endogenously expressed receptors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Molecular design: deuteration at a metabolic soft spot and absence of partial agonism
Two oral formulations: immediate-release capsule for attacks and extended-release tablet for prophylaxis
Pharmacodynamics
Bradykinin challenge in healthy volunteers: design
Bradykinin challenge in healthy volunteers: composite EC50 and EC85
Bradykinin challenge in healthy volunteers: duration of effect compared with icatibant
Bradykinin challenge in non-human primates
“Deucrictibant / bradykinin challenge” (opens the source at this quote in a new tab)
“Maximal activity at 1 hour” (opens the source at this quote in a new tab)
“Icatibant / bradykinin challenge” (opens the source at this quote in a new tab)
“Maximal activity at 2 hours” (opens the source at this quote in a new tab)
EC85 as a surrogate threshold for onset and duration of clinical effect
Bradykinin challenge as the basis for dose selection and its consistency with phase 2 results
Onset of clinical effect relative to therapeutic exposure in RAPIDe-3
Pharmacokinetics
Single ascending doses of oral solution in healthy volunteers: absorption, dose proportionality, and half-life
Single ascending doses of oral solution in healthy volunteers: pharmacokinetic parameters
| Parameter | 1 mg fasted | 2 mg fasted | 4.5 mg fasted | 12 mg fasted | 22 mg fasted | 22 mg after high-calorie, high-fat breakfast |
|---|---|---|---|---|---|---|
| Cmax, ng/mL, mean (SD) | “11.1 (4.03)” | “19.8 (3.70)” | “32.9 (7.66)” | “97.3 (28.1)” | “213 (49.5)” | “145 (56.2)” |
| AUClast, ng.h/mL, mean (SD) | “33.0 (25.9)” | “66.0 (27.0)” | “129 (56.5)” | “369 (194)” | “681 (113)” | “1015 (490)” |
| t1/2, h, mean (SD) | “3.49 (1.32)” | “4.26 (1.91)” | “4.36 (1.29)” | “4.25 (0.831)” | “5.61 (0.707)” | “5.31 (1.54)” |
| CL/F, L/h, mean (SD) | “42.3 (25.4)” | “33.8 (11.9)” | “37.6 (11.1)” | “40.9 (20.7)” | “31.5 (5.60)” | “25.3 (9.77)” |
Food effect after a single 22 mg dose of oral solution
Company summary of phase 1 pharmacokinetics with and without food
Population pharmacokinetic model from the bradykinin challenge study
Immediate-release capsule 2 x 10 mg in healthy volunteers
Immediate-release capsule in adults with HAE in a non-attack state (RAPIDe-1 part 1)
Immediate-release capsule 2 x 20 mg compared with the extended-release tablet 40 mg in healthy volunteers (PHA022121-C020)
| Parameter | Deucrictibant IR capsule 2 x 20 mg | Deucrictibant XR tablet 40 mg |
|---|---|---|
| Cmax, ng/mL, mean (SD) | “547 (193)” | “87.2 (25.5)” |
| tmax, hours, median (range) | “1.00 (0.50–1.50)” | “5.03 (3.98–24.00)” |
| AUCinf, ng⋅h/mL, mean (SD) | “1799 (745)” | “1547 (699)” |
| t1/2, hours, mean (SD) | “5.10 (1.28)” | “5.72 (1.70)” |
| CL/F, L/hours, mean (SD) | “26.5 (12.7)” | “31.5 (14.7)” |
Half-life and peak concentration of the 20 mg immediate-release capsule compared with icatibant
Adolescents: single-capsule pharmacokinetics in a non-attack state (RAPIDe-3)
Multiple ascending doses of oral solution in healthy volunteers: accumulation, steady state, and half-life
Metabolism: CYP3A4 and an active metabolite
Mass balance study and Japanese bridging study
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information for deucrictibant
Not applicable.
Participants exposed across the clinical studies, data cutoff June 10, 2026
Integrated cardiovascular adverse events across phase 1, phase 2, and phase 3 studies
Concentration-QTc analysis of pooled phase 1 studies
Nonclinical cardiovascular safety and hERG channel assay
Thorough QT study waivers accepted by the FDA
FDA clinical hold based on repeat-dose rat toxicology findings, August 2022
Clinical hold lifts: on-demand IND in June 2023 and prophylaxis IND in January 2024
Strong CYP3A4 inhibitors and inducers excluded from the phase 3 on-demand trial
Immediate-release capsule in the phase 3 trial (RAPIDe-3): adverse events in the safety analysis set
Immediate-release capsule in the phase 2 trial (RAPIDe-1): severity and seriousness of adverse events
Phase 1 tolerability of single and multiple doses in healthy volunteers
Prophylaxis trial of the extended-release tablet (CHAPTER-3): safety and cardiovascular outcomes over 24 weeks
Prophylaxis trial with twice-daily immediate-release capsules (CHAPTER-1), randomized part: treatment-related adverse events
Prophylaxis trial (CHAPTER-1) open-label extension: long-term cardiovascular outcomes
Combined use of the immediate-release capsule and extended-release tablet: estimated exposure and nonclinical safety margins
Special populations
Adolescents aged 12 to 17 years: eligibility and enrollment in the phase 3 trial
Children younger than 12 years: EU paediatric investigation plan
“Age appropriate oral solid dosage form” (opens the source at this quote in a new tab)
“Capsule, soft” (opens the source at this quote in a new tab)
“Prolonged-release tablet” (opens the source at this quote in a new tab)
“Treatment of hereditary angioedema” (opens the source at this quote in a new tab)
Older adults: upper age limit and participants aged 65 years or older in the phase 3 trial
| Age group | RAPIDe-3 enrolled participants (N = 134), n (%) |
|---|---|
| Aged 12 to younger than 18 years | “10 (7.5)” |
| Aged 18 to younger than 65 years | “116 (86.6)” |
| Aged 65 years or older | “8 (6.0)” |
Older adults: age limit of the phase 1 concentration-QTc population
Pregnancy and lactation: exclusion from the on-demand trials
Pregnancy and fertility: nonclinical reproductive studies
Hepatic impairment: dedicated pharmacokinetic study and exclusion from the on-demand trials
Renal impairment: dedicated pharmacokinetic study and exclusion from the phase 3 trial
Japanese, Chinese, and Caucasian participants: extended-release tablet multi-ethnicity study
Drug/Drug, drug/disease interactions
Effects of other drugs on Deucrictibant
Strong CYP3A4 inhibitor: itraconazole interaction study
Moderate CYP3A4 inhibitor: verapamil interaction study (PHA022121-C016)
Gastric acid-reducing agent: rabeprazole interaction study with the extended-release tablet (PHA022121-C014)
CYP3A4 inhibitors and inducers excluded from the phase 2 trials
Effects of Deucrictibant on other drugs
CYP1A2, CYP2C19, and CYP3A4 substrates: probe cocktail study
CYP3A4 activity after 10 days of twice-daily dosing: 4β-hydroxycholesterol marker
P-gp and BCRP substrates: digoxin and rosuvastatin study with the extended-release tablet (PHA022121-C017)
Dosing and administration
Dosage
Intended commercial dose: one 20 mg immediate-release capsule
Phase 3 regimen: second capsule 4 hours or later for persisting or progressing non-laryngeal attacks
Phase 3 regimen: washout of at least 72 hours between treated attacks
Use of a second capsule in the phase 3 primary efficacy set of 88 participants with paired attacks
Phase 2 dose range: 10, 20, and 30 mg as a single dose of three capsules
Open-label extension regimen: 20 mg in adults and adolescents (RAPIDe-2 part B)
Combined use with the extended-release tablet during prophylaxis: modeled dosing scenarios
Administration
Self-administration after investigator-confirmed attack qualification in the phase 3 trial
Attacks eligible for treatment in the phase 3 trial
Packaging in the phase 3 trial: one capsule per blister wallet
Capsule ingestion during laryngeal and abdominal attacks
Administration with respect to food
Access and distribution
Commercial preparation for a United States launch
Manufacturing, packaging, and distribution
Expanded access program in the United States (NCT07759141)
Continued investigational access through the RAPIDe-2 open-label extension
Specialty pharmacy or limited distribution arrangements
No evidence found.
Co-prescribed/Concomitant therapies
RAPIDe-3: concomitant long-term prophylaxis permitted
RAPIDe-3: long-term prophylaxis agents used by participants who treated at least one attack
| Long-term prophylaxis | Deucrictibant (n=101) | Placebo (n=100) | Overall participants (n=113) |
|---|---|---|---|
| Any concomitant long-term prophylaxis | “20 (20%)” | “24 (24%)” | “26 (23%)” |
| Lanadelumab | “8 (8%)” | “10 (10%)” | “11 (10%)” |
| Berotralstat | “5 (5%)” | “7 (7%)” | “7 (6%)” |
| C1-esterase inhibitor | “4 (4%)” | “5 (5%)” | “5 (4%)” |
| Danazol | “3 (3%)” | “2 (2%)” | “3 (3%)” |
RAPIDe-3: second capsule and conventional rescue medication rules
RAPIDe-1: long-term prophylaxis excluded and rescue medication rules
RAPIDe-2 Part B: concomitant long-term prophylaxis permitted
Combined use of the immediate-release capsule during extended-release prophylaxis
CHAPTER-1: icatibant treatment of breakthrough attacks during deucrictibant prophylaxis
Effect of Deucrictibant on quality measures
No evidence found.
Product comparison
Deucrictibant: route, dose, and time to onset of symptom relief in RAPIDe-3
Deucrictibant: redosing and rescue medication in RAPIDe-3
Sebetralstat: route, dose, redosing, and time to beginning of symptom relief in KONFIDENT
Icatibant: route, dose, redosing, and time to symptom reduction in its placebo-controlled trial
Ecallantide: route, administration setting, redosing, and outcome measures in its two trials
Plasma-derived C1 esterase inhibitor: route, dose, and time to onset of relief in its placebo-controlled trial
Recombinant C1 esterase inhibitor: route, dose, redosing, and time to beginning of relief in its placebo-controlled trial
Cross-trial comparison with sebetralstat and icatibant as stated by the RAPIDe-3 investigators
Redosing and rescue medication with deucrictibant and sebetralstat as stated by the RAPIDe-3 investigators
Pharmacokinetics and potency of deucrictibant and icatibant as stated by the RAPIDe-3 investigators
Safety relative to icatibant as stated by the RAPIDe-3 investigators
Company statement: absence of head-to-head comparison with icatibant
Company statement: anticipated differentiation of the immediate-release capsule
Company statement: anticipated position relative to the current standard of care
Indirect comparison of sebetralstat with recombinant C1 esterase inhibitor funded by KalVista
“Based on a systematic literature review and feasibility assessment, only the pivotal trial for intravenous rhC1INH (NCT01188564) reported necessary data for a comparable primary efficacy endpoint (time to beginning of symptom relief) to enable an ITC with oral sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The fixed-effects model found no significant differences in time to beginning of symptom relief between sebetralstat 300 mg and rhC1INH 50 IU/kg (hazard ratio [95% credible interval], 0.96 [0.42–2.15] to 1.19 [0.58–2.45]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, the location of on-demand treatment administration differed, with the KONFIDENT trial being the first phase 3 trial to allow patients to treat at home; the impact of this difference cannot be assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was supported by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indirect comparison of recombinant C1 esterase inhibitor with sebetralstat funded by Pharming
“In the primary analysis, rhC1-INH was associated with a statistically significant 4.5-fold increased likelihood of achieving complete resolution (HR 4.52; 95% CI 2.84–7.18) and a significant 82% reduction in redosing (OR 0.18; 95% CI 0.06–0.53) vs sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients in the rhC1-INH trials had a severe or very severe attack at baseline based on the PGI-S scale [3, 4], whereas patients enrolled in the KONFIDENT trial had a range of baseline attack severities, with only 17.5% of patients having severe or very severe attacks at baseline [8].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rhC1-INH trials required clinic visits for assessment and treatment, resulting in delayed rhC1-INH administration (median 242 min) [3, 4], whereas the KONFIDENT trial allowed for self-administration of sebetralstat (median 41 min) [8].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In these scenario analyses, the HRs for TTCR were 1.41 (95% CI 0.63–3.18) and 9.76 (95% CI 4.94–19.29).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rapid Service and Open Access fees were funded by Pharming Healthcare, Inc., Warren, NJ, USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methodological critique of the Pharming-funded indirect comparison
Health technology assessment appraisal of the sebetralstat indirect comparison
Cross-trial comparison caveats: guideline statement
“Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct comparisons among these options are limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events are limited to headache, nevertheless, long-term data from extension studies and RWE are still lacking, precluding appropriate comparisons between this novel agent and existing first-line ODT options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cross-trial comparison caveats: infeasibility of a head-to-head trial
“Lastly, it is recognized that the ideal comparison between therapies would be a randomized, double-blind, head-to-head clinical trial (double dummy design).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, in the context of HAE, there are multiple reasons making such an RCT infeasible, including challenges in aligning time to treatment for an oral versus an injectable treatment, and the ability to use a double-blind approach for evaluating oral versus injectable treatments, due to expected skin reactions with the latter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because no head-to-head trials have evaluated on-demand therapies for hereditary angioedema (HAE), variability in study designs and outcome definitions across clinical trials limits direct interpretation of relative efficacy, including time to complete resolution (TTCR) and the need for redosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral therapies developed for prophylaxis and on-demand treatment
“Over the past 6 years two oral therapies have been developed for HAE to include berotralstat for long term prophylaxis (LTP) and sebetralstat for on-demand therapy (ODT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Presently, deucrictibant, another oral HAE therapy, is under investigation and appears effective for LTP and ODT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place of product in therapy
Disease description
Definition and etiology
Definition: recurrent bradykinin-mediated angioedema
“Angioedema is a localized, self-limiting, asymmetric, and disfiguring non-inflammatory edema of the subcutaneous and submucosal tissues that arises because of increased vascular permeability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HAE comprises a group of genetic disorders characterized by recurrent episodes of angioedema, inherited across generations and typically mediated by bradykinin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Classification: HAE with C1-INH deficiency (types 1 and 2) and HAE with normal C1-INH
“HAE (ORPHA:91378, OMIM: PS106100) is most commonly caused by a deficiency of C1 inhibitor (C1-INH), which can be confirmed through biochemical and genetic testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is subclassified into type 1 HAE (quantitative deficiency) and type 2 HAE (dysfunctional protein).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, in 2000, a new type of HAE was described in patients with normal C1-INH function, a form initially known as HAE type 3 but currently called HAE with normal C1-INH (HAE-nC1-INH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic cause: SERPING1 and F12 variants
Penetrance, transmission risk, and de novo variants
“HAE-C1-INH is an autosomal dominant disorder characterized by high penetrance, with only about 5% of mutation carriers remaining asymptomatic over their lifetime.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The risk of parent–child transmission is 50%, but up to 25% of cases result from de novo genetic mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distribution of HAE types: Swedish population-based cohort
Genetic causes of HAE with normal C1-INH
“Abnormalities in proteins/genes, such as factor XII (encoded by the F12 gene), plasminogen (PLG), angiopoietin-1 (ANGPT1), kininogen 1 (KNG1), myoferlin (MYOF), and heparan sulfate-3-O-sulfotransferase 6 (HS3ST6), have been associated with these forms of HAE (collectively HAE-nC1-INH), and the involvement of bradykinin has not been confirmed in all cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HAE of unknown origin (ie, with negative genetic test results) is referred to as HAE-UNK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HAE-nC1-INH forms also usually follow an autosomal dominant inheritance pattern, although autosomal recessive forms have been reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of hereditary angioedema
Annual incidence of diagnosed HAE type 1 and 2: Finnish national register
Incidence of treated HAE: Swedish National Prescribed Drug Register, 2024
Prevalence of hereditary angioedema
Prevalence and incidence: systematic literature review
Pooled diagnosed annual prevalence: combined HAE types and 95% confidence interval
Pooled diagnosed annual prevalence by HAE type and by region
United States prevalence of all HAE types: commercial claims database, 2018 to 2020
“No US prevalence for all types of HAE has been estimated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For 2018, 2019, and 2020, the claims-based algorithm yielded overall annual unadjusted HAE prevalence estimates per 100,000 and number of people diagnosed with HAE of 2.67, 9559; 2.61, 9341; and 2.43, 8694, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The corresponding estimates based on expert physician analysis were 2.13, 7602; 2.03, 7275; and 1.84, 6595, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our calculations (which exceed the frequently cited 2:100,000 prevalence for HAE with C1 inhibitor deficiency) afford a real-world projected prevalence encompassing all types of HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Worldwide pooled prevalence: systematic review and meta-analysis of 24 studies
“Twenty-four studies from 2000 to 2024 were included in the analysis, describing 11,245 cases of HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled prevalence of HAE was 1.22 cases per 100,000 people (95% confidence interval [CI]: 0.91, 1.53), with lower prevalences reported in Asia and Africa compared to Europe and North America.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HAE type 1 made up most of the cases, with a slight female predominance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of diagnosed HAE type 1 and 2: Finnish national register
Minimum prevalence of HAE types 1 and 2: United Kingdom survey of 37 centers
“The survey identified 1152 patients with HAE-1/2 (58% female and 92% type 1), 22 patients with HAE with normal C1 inhibitor, and 91 patients with acquired C1 inhibitor deficiency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Data were provided by 37 centers across the United Kingdom.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This gives a minimum prevalence of 1:59,000 for HAE-1/2 and 1:734,000 for acquired C1 inhibitor deficiency in the United Kingdom.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Minimal prevalence in the Asia Pacific region: survey of 12 countries and territories
“Completed questionnaires were received from 14 representatives of 12 member countries and territories, representing 46% of the world population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall minimal prevalence of HAE in the AP region was 0.02/100,000 population, with significant heterogeneity across different centers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Population prevalence of HAE with C1-INH deficiency: South Australia, 2021 to 2022
“Case ascertainment was conducted over 18 months from January 2021 to July 2022, using a range of approaches with the aim of identifying all people with C1INH-HAE in South Australia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 35 people with HAE in South Australia, yielding a population prevalence of 1 in 52,400, in line with average established international prevalence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are relatively few systematic population prevalence studies, with reports from various countries of between 1 in 20,000 and 1 in 150,000.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company statement: HAE prevalence worldwide, in the United States, and in the European Union
Company statement: prevalence by type of bradykinin-mediated angioedema
Natural history, survival, and mortality
Long-term course: onset age, symptom-free years, and severity by sex
“Clinical symptoms started at a mean age of 11.2 (SD 7.7) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the following cumulative 5736 years, only 370 (6.5%) symptom-free years occurred.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On average, women had a more severe course of the disease than men.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with early onset of clinical symptoms were affected more severely than those with late onset.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Course of an attack and attack frequency without treatment
“The episodes typically involve nonpruritic, nonpitting swelling that worsens over the first 24 hours and gradually subsides over the next 48 to 72 hours, usually lasting no more than 5–7 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Untreated patients with HAE may experience attacks every 7–14 days on average, although some report attacks as frequently as every 3 days, while others may experience them rarely or never.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality from laryngeal attacks: German cohort of 728 patients
“Of the 214 patients who had died, 70 asphyxiated during a laryngeal attack.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality by asphyxiation was higher in patients with undiagnosed HAE-C1-INH (63 cases) than in patients with diagnosed HAE-C1-INH (7 cases).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality from laryngeal attacks: Brazilian reference-center cohort of 433 patients
“A total of 75 fatal events were evaluated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Only 10 of 75 patients were given the diagnosis of HAE before death, and the HAE diagnosis was made after death in 65 of 75 patients using verbal autopsy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The final cause of death after the investigation was asphyxiation owing to LE in 39 of 75 (52%) and deaths owing to other causes in 36 of 75 (48%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The life span of patients who died of LE was reduced by 20 years compared with those who died of other causes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality from laryngeal edema: review of 23 real-world studies
“The analyzed studies included 3292 patients and 411 deaths from asphyxia due to laryngeal edema.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Death rates from laryngeal edema had an average of one death for every 20 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage among deaths in general associated with laryngeal edema was evaluated in three studies (32.7%, 44.4%, and 56%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States death certificates, 1979 to 2010
“The age-adjusted death rate for hereditary angioedema decreased from 0.28 (95% confidence interval [CI] 0.25-0.32) to 0.06 (95% CI 0.05-0.08) per million persons per year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lack of specific coding for acquired angioedema most likely explains the observed association between cancer and hereditary angioedema.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Family deaths from HAE attacks: US patient registry
“Morbidity surrogates including emergency department visits, hospitalizations, unnecessary abdominal surgeries, and intubations were strikingly high as was mortality with 36.9% of HAE-C1INH and 15.4% of HAE-nl-C1INH participants reporting family members who died from a HAE attack.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
All-cause mortality: Swedish population-based cohort
“In the current study, there was no increased risk of death (OR 0.69; 95% CI 0.38–1.26) among HAE patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonetheless, the mortality among HAE patients during the last decade seems to be low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rising prevalence attributed to decreased mortality: Finnish national register
Factors associated with in-hospital mortality: US Nationwide Inpatient Sample, 2021
Risk of death from laryngeal edema without a diagnosis
Fatal laryngeal attacks: time to death and treatment received, Brazilian reference-center cohort
“Time from onset of symptoms to seeking medical assistance was a median of 4 hours, and the time to death was a median of 8 hours.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three patients received fresh-frozen plasma and none received medications specific to HAE attacks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Throat pain or discomfort was the most common symptom, experienced by 71.8% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
On-demand treatment and the risk of asphyxiation
“All patients with confirmed HAE, even if asymptomatic, must have access to ODT, as the risk of a severe attack is unpredictable and persists throughout life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ODT, regardless of HAE endotype, reduces the risks of asphyxiation, abdominal symptoms, and functional impairment of the limbs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden before and after on-demand therapies became available: US patient survey
“Patients at a United States HAE Association summit meeting were asked to rate the burden of HAE currently and compare by recall with 2009 when these therapies were not available.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Responses were obtained from 134 self-identified HAE subjects: 85 type I, 21 type II, and 28 with normal C1 inhibitor (C1INH).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Burden of disease showed significant improvement in all domains except worry about children inheriting HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, our study shows that a substantial burden of illness remains for HAE patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Company statement: attack frequency and course of untreated attacks
Company statement: airway attacks and risk of asphyxiation
Pathophysiology
Bradykinin generation: activation of prekallikrein to plasma kallikrein
“In HAE-C1-INH, bradykinin is the primary mediator of swelling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This molecule arises from cleavage of high-molecular-weight kininogen by plasma kallikrein, which is activated from prekallikrein by factor XII.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The resulting bradykinin nonapeptide increases vascular permeability and induces swelling (angioedema) through a specific receptor, B2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role of C1 inhibitor in regulating the kallikrein-kinin system
“C1-INH is a serine protease inhibitor protein synthesized in hepatocytes that is crucial in regulating the plasma kallikrein–kinin system (KKS) and preventing excessive bradykinin production.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HAE-C1-INH is caused by mutations in SERPING1, which encodes C1-INH, leading to reduced levels or impaired activity of C1-INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This deficiency in turn leads to uncontrolled activation of the KKS and excessive bradykinin production, with bradykinin acting as the key mediator of the condition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bradykinin and vascular permeability
Evidence for bradykinin as the mediator of attacks: plasma levels and the B2 receptor knockout model
“In 1983, a pivotal study by Fields et al. implicated bradykinin as the likely primary mediator responsible for angioedema attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This hypothesis was further supported in 1999 by Nussberger et al, who analyzed plasma samples from individuals with HAE and reported elevated bradykinin levels in blood drawn from edematous sites compared to unaffected areas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Shortly thereafter, in 2002, a landmark experimental study using a double-knockout murine model deficient in both C1 inhibitor (C1-INH) and bradykinin B2 receptor (Bk2R) further confirmed the critical role of C1-INH deficiency and bradykinin in the pathogenesis of HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Kinin receptors: bradykinin B1 and B2 receptors
“Bradykinin (BK)-related peptides, the kinins, are released from kininogens by kallikreins and exert various physiological and pathological effects via 2 related G protein-coupled receptors (GPCRs) termed the bradykinin B1 and B2 receptors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While kinins and their receptors mediate compensatory and protective vasodilator effects under various pathological conditions, they are also mediators of inflammation, producing plasma extravasation and edema and pain” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bradykinin B2 receptor as the mediator of vascular permeability and swelling
“which leads to the overproduction of bradykinin and activation of bradykinin B2 receptors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This increases vascular permeability and results in angioedema attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bradykinin is rapidly metabolized by endogenous metalloproteases including angiotensin-converting enzyme (ACE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increased vascular permeability and swelling induced by bradykinin are primarily mediated through the bradykinin B2 receptor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bradykinin binds to and stimulates the bradykinin B2 receptor, thereby mediating vasodilatation and increased capillary permeability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endothelial B2 receptor signaling: adherens junction disruption and resealing
Bradykinin production pathways and blockade at the receptor
Kallikrein-kinin system targets of oral treatments
“Currently approved and investigational oral treatments for HAE target components of the kallikrein‐kinin system, including plasma kallikrein (PKa), activated factor XII (FXIIa), or bradykinin B2 receptor (B2R; Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PKa inhibitors (e.g., berotralstat, sebetralstat, ATN249, VE‐4666, and VE‐4062) and FXIIa inhibitors prevent bradykinin generation by preventing cleavage of high molecular weight kininogen, whereas B2R antagonists (e.g., deucrictibant) block bradykinin binding.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mediators of swelling in HAE with normal C1-INH
“Current evidence indicates that excessive bradykinin generation is still involved in most cases (HAE-FXII, HAE-PLG, HAE-KNG, HAE-HSST, and HAE-CPN).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, other mediators such as VEGF and angiopoietin have emerged as candidate contributors, potentially increasing vascular permeability either directly (HAE-MYOF, HAE-DAB2IP) or indirectly (HAE-ANGPT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company statement: bradykinin B2 receptor activation in angioedema
Diagnosis
Systematic literature review of HAE disease burden: diagnostic delay
Guideline recommendation: initial C1-INH functional assay
“We recommend that all patients for whom HAE is suspected undergo an initial assessment with a C1-INH functional assay, as long as it is performed by a specialized laboratory using an accurate, validated method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If the C1-INH functional assay is unavailable or unreliable, the diagnosis can still be confirmed through quantitative C1-INH measurement and/or genetic testing for SERPING1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory findings: C4, C1-INH antigen, and C1-INH function
“C4 levels are low in 90%–95% of patients with HAE-C1-INH during asymptomatic periods and are almost always low during acute attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In HAE type 1, C1-INH antigen levels are reduced, whereas in HAE type 2, they are normal or elevated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In HAE-C1-INH, functional activity is typically less than 50% of normal levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendations: genetic testing and cascade family testing
“We recommend genetic testing for HAE-nC1-INH in patients for whom there is high clinical suspicion of HAE and who have normal C1-INH functional assay results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend cascade family testing for HAE when an index case is diagnosed, either through C1-INH testing or genetic testing, as appropriate based on age and diagnosis (HAE-C1-INH vs. HAE-nC1-INH).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay over time
“Fortunately, diagnostic delay in HAE has declined considerably in the last decades, from an average of 21 years in the 1970s to around 7–10 years currently” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Under 40% of patients receive a diagnosis within 1 to 3 years after symptom onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at diagnosis and diagnoses preceding HAE: Finnish national register
Laboratory findings in HAE with normal C1-INH and acquired C1-INH deficiency
“Results for all 3 of these tests are normal in HAE-nC1-INH and in ACE inhibitor–induced angioedema and decreased in acquired C1-INH deficiency (ie, acquired angioedema [AAE-C1-INH]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C4, C1-INH antigenic levels, and functional activity are within normal ranges in HAE-nC1-INH and typically reduced in AAE-C1-INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, negative genetic test results should not be considered definitive for excluding HAE-C1-INH or HAE-nC1-INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical features suggesting HAE
“Attacks not accompanied by urticaria, except in cases of HAE-CPN1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No response to treatment of attacks with epinephrine, H1-antihistamines, or glucocorticoids” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Positive family history, especially if suggestive of autosomal dominant inheritance” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company statement: time from symptom onset to diagnosis
Clinical presentation - signs and symptoms
Gastrointestinal symptoms: intestinal attacks
Airway symptoms: obstruction risk
Distribution of attacks by site: edema episodes reported by 221 patients
“Skin swellings, including extremity, facial, genital, and trunk swellings, and abdominal attacks occurred in 97.4% of all edema episodes of the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The other episodes were laryngeal edema (0.9%); edema of the soft palate (0.6%); tongue swellings (0.3%); headache episodes (0.7%); episodes affecting urinary bladder (0.3%), chest (0.2%), muscles (0.4%), joints (0.1%), kidneys (0.1%), and esophagus (0.05%), and were partly combined with other edema episodes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Abdominal and laryngeal involvement: proportion of patients affected
“Abdominal involvement occurs in 70%–90% of all individuals and is associated with high morbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Laryngeal involvement, although accounting for less than 1% of all attacks, poses a risk of death and occurs at least once in about half of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Airway symptoms: phases of fatal laryngeal attacks
“Phase 1, the predyspnea phase, lasted on average for 3.7 ± 3.2 hours (range, 0-11 hours).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Phase 2, the dyspnea phase, lasted on average for 41 ± 49 minutes (range, 2 minutes to 4 hours).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prodromal symptoms and erythema marginatum
“Non-specific prodromal symptoms are common and can include anxiety, nausea, paresthesia, and fatigue.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One third of patients with HAE, especially children, experience erythema marginatum (a nonpruritic form of flat, figurate erythema) as an initial manifestation, which may mimic the skin lesions of urticaria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Abdominal symptoms: presentation resembling an acute surgical abdomen
“Abdominal attacks can cause severe abdominal pain, nausea, and vomiting and may lead to unnecessary abdominal surgery, as the clinical presentation can resemble an acute surgical abdomen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In some cases, intestinal angioedema may be accompanied by ascites and, very rarely, by hypovolemic shock.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laryngeal symptoms: frequency, age at first episode, and time to maximum swelling in 123 patients
“Information on 123 patients with hereditary angioedema was obtained from medical histories and reports by the general practitioners, emergency physicians, and hospitals involved.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-one patients (49.6%) experienced a total of 596 laryngeal edema episodes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The ratio of laryngeal edema episodes to skin swellings and abdominal pain attacks was approximately 1:70:54 in patients who had laryngeal edema.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) age at the first laryngeal edema was 26.2 (15.3) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean interval between onset and maximum development of laryngeal edema was 8.3 hours.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In adults, the interval between onset of symptoms and acute risk of asphyxiation is usually long enough to allow for use of appropriate emergency procedures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Laryngeal symptoms: facial edema as a risk factor
Laryngeal attacks during long-term prophylaxis: systematic review
“Attacks at all anatomic locations, including laryngeal attacks, continued to occur in patients who received LTP, regardless of the LTP agent” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, both interventional and observational studies reported that laryngeal attacks accounted for between 2%-7% of all attacks in patients who received LTP with pdC1INH, lanadelumab, danazol, or TA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prodromal symptoms: frequency, specificity, and sensitivity for predicting an attack
“Prodromal symptoms, traditionally reported in up to 65%–70% of attacks, present an opportunity for early intervention but may lead to overuse of ODT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recent studies indicate that although the specificity of prodromal symptoms for an attack exceeds 95%, their sensitivity for accurately predicting an attack varies from 18% to 64%, depending on the attack site.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prodromal symptoms: prospective study of 48 patients
“In the present study, a cohort of 48 HAE patients prospectively reported four events of prodromes followed by attack, attacks not preceded by a prodrome and incidents with only a prodrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We received reports on 119 prodromes and 192 attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority experienced a prodrome before at least one of their attacks, and 64% affirmed that they can predict an oncoming attack by having a prodrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean duration of prodromes was significantly shorter than attacks, and prodromes overlapped the attack in 24.3% of cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sensitivity of the prodrome as a predictor of attack was 95% to 99%, and specificity 18% to 64%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pain and swelling during attacks: European patient survey of 186 patients
“The HAE Burden of Illness Study in Europe was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE from the patient perspective via a one-time survey, which included items on clinical characteristics and physical and emotional impacts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One hundred eighty-six patients participated; 59% reported having an attack at least once a month, 67% reported moderate-to-severe pain during their last attack, and 74% reported moderate-to-severe swelling.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common sites of the last attack were the abdomen and extremities; 24% experienced an attack in more than one site.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychological symptoms during attacks: anxiety in the KONFIDENT trial
“Participants in the randomised, double‐blind, phase 3 KONFIDENT trial (NCT05259917) treated attacks with sebetralstat 300 mg, 600 mg or placebo as early as possible after onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 115 (44%) attacks were rated as inducing moderate‐to‐extreme anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Female sex, shorter time since HAE diagnosis and greater attack severity were associated with greater anxiety at treatment administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attack site, severity, and duration with and without on-demand treatment: Milan cohort of 227 patients
“From January 2009 to August 2014, data on attacks and treatments were collected from 227 patients from our centre in Milan.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 4244 attacks were reported; 50% were treated with approved therapies (pdC1-INH or icatibant), 15% were with tranexamic acid, and 35% were not treated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Attack locations were peripheral cutaneous (46%), abdominal (34%), multiple (12%), facial (5%) and laryngeal (3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Attack severities were moderate (48%), mild (28%) and severe (24%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median attack duration (data available for 2393 attacks) with approved therapies was 10 h, significantly shorter than without treatment (45 h) or with tranexamic acid (38 h).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Attack site and duration with and without on-demand treatment: Milan angioedema centre, 2014
“This is a prospective observational study conducted at Milan angioedema centre between 1 January and 31 December 2014.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 133 of 167 patients (79.6%) reported 1508 attacks during the study period, with mean incidence of 11 attacks per patient per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attacks were more often peripheral (47.6%), followed by abdominal attacks (39.4%), facial attacks (6.2%) and laryngeal attacks (4.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both icatibant and pdC1-INH significantly reduced attack duration compared with no treatment (median times from onset 7, 10 and 47 hours, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, shorter time to treatment was associated with a small (2%) but significant positive effect on remission rates (HR 0.98, 95% CI 0.97 to 0.99), suggesting that each additional hour between onset of symptoms and treatment administration would increase the chance of a faster resolution by approximately 2%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attack progression with delayed or no treatment: US patient survey
“Patients with HAE (type I or II) aged 12 years or older with more than or equal to 1 treated (Treated Cohort) or untreated (Untreated Cohort) attack in the past 3 months were recruited by the US HAE Association.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Time to treatment paralleled changes in attack severity (33% mild attacks treated in <1 hour vs 67% in ≥1 hour, progressed to moderate/severe) and mean duration (<1 hour: 0.7 day; >8 hours: 2.7 days).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the Untreated Cohort (n = 20), 50% of the respondents describing their last untreated attack as mild experienced progression to moderate or severe and 25% reported spread to another site including the larynx and face.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Untreated attacks lasted a mean of 2.3 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Attack severity mix at treatment in placebo-controlled trials of an oral on-demand treatment
“Sebetralstat, an oral plasma kallikrein inhibitor, was evaluated in 2 randomized, placebo-controlled clinical trials, which instructed early treatment of attacks with no minimum severity requirement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“377 attacks were treated: 87 with sebetralstat 300 mg; 151 with sebetralstat 600 mg; 139 with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline severity was rated as "Mild" (46.2%), "Moderate" (40.6%), or "Severe"/"Very Severe" (12.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the time of attack onset, 156 attacks (41.4%) were mucosal; of these, 115 (30.5%) were abdominal-only attacks, and 8 (2.1%) were laryngeal attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For sebetralstat 300 mg, sebetralstat 600 mg, and placebo, earlier-treated attacks (43.5%, 55.6%, and 48.0%, respectively) were more likely to be mild compared with later-treated attacks (29.6%, 33.3%, and 31.3%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Presentation of HAE with normal C1-INH
“The clinical manifestations of HAE-nC1-INH are similar to those of HAE-C1-INH, and the 2 are largely indistinguishable based on signs and symptoms alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, in certain HAE-nC1-INH subtypes, angioedema attacks tend to have a later onset and may be accompanied by local hematomas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company statement: symptoms, attack sites, triggers, and prodromes
Long-term morbidity
Cardiovascular, thromboembolic, and autoimmune comorbidity: Swedish population-based cohort
“Increased risk of cardiovascular disease (odds ratio [OR] 1.83; 95% confidence interval [CI] 1.32–2.54), including arterial (OR 6.74; 95% CI 1.89–24.06) and venous thromboembolic disease (OR 4.20; 95% CI 2.42–7.23) as well as hypertension (OR 1.64; 95% CI 1.12–2.39) was seen in HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the risk of autoimmune disease was increased (OR 1.65; 95% CI 1.15–2.35) being particularly pronounced for systemic lupus erythematosus (OR 71.87; 95% CI 8.80–586.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the risk of cancer was not increased.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A two-fold higher prevalence of allergy, asthma, and atopic dermatitis was found (OR 2.19; 95% CI 1.60–2.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity associated with attenuated androgen prophylaxis
Composite venous thromboembolism: reanalysis of the Swedish cohort
“Our analysis revealed that individuals with HAE had a significantly increased risk of composite VTE compared to controls (odds ratio 3.57, 95% confidence interval 2.16-5.81, Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, individuals with HAE did not have a significantly increased risk of composite ATE (odds ratio 1.3, 95% confidence interval 0.81-2.09, Figure 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C1INH is a potent inhibitor of plasma kallikrein, which spans the kallikrein kinin pathway and intrinsic coagulation pathway, and the intrinsic coagulation pathway components activated factor XII and activated factor XI” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity compared with the general US population: US patient registry
“Females with HAE-C1INH had a significant increase in the prevalence of depression, sleep disorders, kidney disease, anemia, and hepatitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cardiovascular comorbidities were significantly reduced in the HAE-C1INH group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Consequences of delayed diagnosis
“Delays in HAE diagnosis can lead to serious consequences, including reduced quality of life (QoL), loss of productivity and income, depression, unnecessary medical interventions, increased healthcare costs, and an imminent risk of death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unnecessary abdominal surgeries, such as appendectomies, along with exploratory diagnostic procedures such as colonoscopy, also are frequent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Presumptive post-traumatic stress disorder: US HAE Association survey
“Participants ≥ 18 with HAE-C1INH were recruited from the US HAE Association: Cohort 1, self-referred; Cohort 2, randomized from the HAEA membership.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of presumptive PTSD based on the PLC-C outcomes was between 20 and 25% in HAE-C1INH participants (n = 77).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diagnosis was correlated with high rates of depression and reduced SF-36 mental domain performance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of hereditary angioedema
Humanistic burden and health-related quality of life
Burden of disease in adults: multinational survey
Multinational adult survey: treatment exposure and quality-of-life outcomes
| Measure | Reported result |
|---|---|
| Participants included | “260” |
| Participants using any long-term prophylaxis | “153 (58.8%)” |
| First-line prophylaxis among prophylaxis users, per study classification | “56/153 (36.6%)” |
| AE-QoL total score, mean ± SD | “42.9 ± 23.2” |
| Participants with AE-QoL total score ≥39 | “137 of 260 (52.7%)” |
| Moderate to severe anxiety by HADS | “69 (26.5%)” |
| Moderate to severe depression by HADS | “27 (10.4%)” |
Health-related quality of life, depression, and work productivity: US patient survey
“A total of 457 HAE patients responded to the survey (response rate, ∼19%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported significantly poorer health-related quality of life versus population norms, based on the SF-12 Physical Component Summary (mean, 43.7 versus 49.6; p < 0.001) and Mental Component Summary (mean, 42.6 versus 49.4; p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HAE patients also had higher mean HDI-SF scores than population norms (8.1 ± 6.5 versus 3.1 ± 3.0; p < 0.001), with 42.5% of HAE patients scoring >8.5, indicative of depressive symptomatology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Productivity was also markedly impaired in all WPAI-GH categories, including 34% overall work impairment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because of their most recent HAE attack, workers lost a mean of 3.3 days; students lost a mean of 1.9 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety and depression: health technology assessment background
Quality of life with subcutaneous prophylaxis compared with on-demand treatment alone: US patient survey
“The greatest improvement in QoL was seen in patients who used novel SC prophylactic therapies, with a 59.5% (p < 0.01) improvement in median impairment scores versus on-demand–only treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, patients who used novel SC prophylactic therapies reported a 77% reduction in the number of attacks each year when compared with those who used on-demand–only treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden despite current therapies: US adult survey
“A web-based survey was conducted from March to April 2025 among 100 US adults with HAE-C1INH currently receiving long-term prophylaxis and/or on-demand therapies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Even with treatment, 80% of respondents reported ≥1 HAE attack in the past year and 61% thought about HAE at least weekly.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mental health was the aspect that respondents felt was most impacted by HAE (54% of respondents), and 73% reported taking ≥2 measures to avoid attack triggers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Several concerns impacted the ability to reach normalization; lifetime use of medication was the most commonly reported concern (68% of respondents).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The greatest unmet needs associated with long-term prophylaxis were cost- and access-related.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Preferences for long-term prophylaxis and willingness to switch: US adult survey
“A total of 150 individuals completed the survey.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents rated effectiveness in preventing attacks and reducing the severity of attacks as the most important LTP attributes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Route of administration and convenience were more than twice as important as dosing frequency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals preferred oral daily therapy to biweekly (54% vs 46%) or monthly injections (54% vs 46%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most individuals (71%) were at least somewhat willing to switch LTP treatments in the next 6 months, particularly those whose HAE was not well controlled, were anxious about taking LTP, were burdened by treating their HAE, or preferred oral administration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life during the last treated attack by time to on-demand treatment: US patient survey
“Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 94 respondents were included in the Treated Cohort, and 20 were included in the Untreated Cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Treated Cohort, the mean (SD) EQ-5D-5L index score was 0.849 (0.2) “Today” and 0.568 (0.3) “During the last treated attack” (Fig. 1A), with the latter score indicative of substantial impairment in HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) index score was 0.667 (0.3) in patients who treated <1 h of attack onset and 0.504 (0.3) in those who treated 5 to < 8 h of attack onset (Fig. 1B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of administration route, reductions in HRQoL and work productivity and increases in activity impairment were generally more pronounced among IV OD users than among SC OD users (mean EQ-5D-5L index score “During the last treated attack”: 0.480 vs 0.615).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with this, IV OD users took longer to administer treatment following attack onset than SC OD users (mean: 5.8 vs 2.8 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Funding for Outcomes Insights was provided by KalVista Pharmaceuticals (Cambridge, MA, USA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work productivity and activity impairment after a treated attack: US patient survey
“Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Treated Cohort, the mean value for attack-related activity impairment was 38% (Fig. 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the 7 days following attack onset, the average rates of absenteeism (work missed due to HAE), presenteeism (impairment while working due to HAE), and overall work impairment were 15%, 35%, and 39%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For respondents with “Mild,” “Moderate,” and “Severe” attacks, the mean level of absenteeism was 5%, 16%, and 35%; the mean level of presenteeism was 29%, 32%, and 68%; and mean overall work impairment was 32%, 36%, and 75%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related anxiety and delay of on-demand treatment: US patient survey
“Patients with HAE (type I or II) aged 12 years or older with more than or equal to 1 treated (Treated Cohort) or untreated (Untreated Cohort) attack in the past 3 months were recruited by the US HAE Association.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the Treated Cohort (n = 94), of the 67% who reported treating their attack early, only 26% administered OD in less than 1 hour.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, 79% (n = 74) reported treatment-related anxiety, which correlated with treatment delay.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Time to treatment paralleled changes in attack severity (33% mild attacks treated in <1 hour vs 67% in ≥1 hour, progressed to moderate/severe) and mean duration (<1 hour: 0.7 day; >8 hours: 2.7 days).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Untreated attacks lasted a mean of 2.3 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Attack-related anxiety in a randomized on-demand treatment trial: KONFIDENT
“Participants in the randomised, double‐blind, phase 3 KONFIDENT trial (NCT05259917) treated attacks with sebetralstat 300 mg, 600 mg or placebo as early as possible after onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The full analysis set included 264 attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 115 (44%) of the attacks were rated as inducing moderate‐to‐extreme anxiety (i.e., GA‐NRS ≥ 4) at treatment administration (Table 1 and Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Female sex, shorter time since HAE diagnosis and greater attack severity were associated with greater anxiety at treatment administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was sponsored by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of injectable on-demand treatment: US and UK patient and caregiver interviews
“The 25 study participants from the US and UK (17 patients; 8 caregivers), who completed the interview, highlighted emotional and logistical reasons for delaying or forgoing injectable on-demand treatment, including fear of needles, portability, and complexity of administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants reported a dislike of needles, pain associated with injection of the medicine, and the need to go to a hospital or medical center as treatment-related reasons for delaying or opting not to treat an attack.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of participants (80%) reported not treating every attack; all participants described delaying treatment intentionally or unintentionally at least once.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants expressed interest in an oral on-demand treatment for reasons including portability, pain-free administration, and ability to treat attacks earlier.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was supported by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Carrying, delaying, and not treating attacks with on-demand treatment: US patient survey
“People living with HAE were recruited by the US Hereditary Angioedema Association (HAEA) to complete a 20-minute online survey between September 6, and October 19, 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents included 107 people with HAE, 80% female, 98% adults (≥ 18 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients (63.6%) reported that they did not carry on-demand treatment at all times when away from home.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common reason for not carrying on-demand treatment when away from home was ‘prefer to treat at home’ (72.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 86% of respondents reported delaying on-demand treatment, despite recognizing the initial onset of an HAE attack and despite 97% of patients agreeing that it is important to recover quickly from an HAE attack.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, one of every five (20%) HAE attacks are untreated (24% amongst on-demand only patients; 15% amongst prophylaxis patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This work was sponsored by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration-site adverse drug reactions with parenteral on-demand treatments: FDA Adverse Event Reporting System
“We searched the FAERS database from October 1, 2009, to March 31, 2022, for reports of all FDA-approved on-demand therapies for HAE: plasma-derived C1-inhibitor (pdC1-INH), ecallantide, icatibant, and recombinant C1-inhibitor (rhC1-INH).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The highest reported rates of administration-site ADRs per year were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Conclusion: Real-world data from FAERS were generally consistent with adverse events reported in clinical trials and suggest that patients experience substantial treatment burden associated with FDA-approved parenteral on-demand therapies for HAE attacks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It should be noted that ADR rates are not exposure adjusted and are based on spontaneous reporting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights during and between attacks: European patient survey mapped to EQ-5D
“Survey items that overlapped conceptually with the EuroQol 5-Dimensions (EQ-5D) domains (pain/discomfort, mobility, self-care, usual activities, and anxiety/depression) were manually crosswalked to the corresponding UK population-based EQ-5D utility weights.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, a total of 111 HAE-BOIS-Europe participants completed all selected survey items and thus allowed for computation of EQ-5D-based utilities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean utilities for an HAE attack and between attacks were 0.44 and 0.72, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Utilities for an acute attack were dependent on the severity of pain of the last attack (0.61 for no pain or mild pain, 0.47 for moderate pain, and 0.08 for severe pain).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time trade-off utilities by attack location: general public valuation in England
“Members of the general public in England rated vignettes in TTO interviews, which included a visual analogue scale (VAS) component.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TTO analysis was based on vignette valuation completed by 100 members of the general public.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TTO values were as follows: attack-free, 0.783 (standard deviation [SD] 0.316); hand: 0.582 (SD 0.380); facial: 0.483 (SD 0.448); abdominal: 0.345 (SD 0.458); and laryngeal: 0.128 (SD 0.529).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by BioCryst Pharmaceuticals, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights with and without attack symptoms drawn from the literature for an economic model
“Utility values were drawn from the literature” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“citing a utility of 0.51 when experiencing attack symptoms and 0.83 without symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonattack baseline utility and attack utility were implemented for effectiveness calculations; time to attack resolution was considered as well.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-5L utility and its decrement during an attack: Dutch patient survey
“Adult patients with HAE under treatment at the Dutch national center of reference completed a cross-sectional survey in 2021.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The response rate was 78% (69 of 88).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean quality of life in the entire sample was 30.99 as expressed by the AE-QoL and 0.873 as expressed by the EQ-5D-5L utility value.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Utilities dropped by 0.320 points during an angioedema attack.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient-defined attack severity and EQ-5D-5L by attack location: US qualitative study for economic evaluation
Physician-reported attainment of treatment goals: international physician survey
“Of 64 respondents from 32 countries, most (91%) had > 5 years of experience in managing HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 48% of respondents (n = 31/64) reported that < 50% of their patients had achieved the WAO/EAACI HAE treatment goals of total disease control and “normalization” of life at the time of the survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Burden of disease remains a challenge among patients, as reported by their physicians.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by CSL Behring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attacks, on-demand treatment, anxiety, and depression: multinational patient survey
“We conducted a noninterventional, cross-sectional, web-based survey of patients with a self-reported diagnosis of HAE type 1/2 in Australia, Austria, Canada, France, Germany, Spain, Switzerland, and the United Kingdom to gain a comprehensive real-world understanding of the characteristics of HAE and its burden from the perspective of the patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 242 patients (67.4% female; mean [range] age 43.8 [18–92] years) completed the survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported a mean (SD) of 12.5 (14.1) attacks in the past 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most recent attack occurred within the past month in 79.7% of patients; most were of moderate severity, 6.6% affected the larynx, 21.9% lasted ≥ 3 days, and 76.4% were treated with on-demand medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moderate to severe anxiety and depression were reported in 38.0% and 17.4% of patients, respectively, as measured using the HADS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Healthcare costs and resource utilization before and after starting long-term prophylaxis: US commercial claims
“A total of 328 patients were included in this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients (67%) had ≥1 post-index on-demand therapy claim.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During follow-up, 17% and 8% had ≥1 HAE-related ER and inpatient visit, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annualized total HAE-related healthcare costs per patient were $165,348 pre-LTP and $515,333 post-LTP, driven by increased LTP pharmacy costs (mean $395,845 PPPY) and partially offset by reductions in medical costs (ER/inpatient, mean $8344 PPPY).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare costs with lanadelumab compared with berotralstat: US claims
“Fifty-seven lanadelumab- and 32 berotralstat-treated patients were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total HAE treatment costs were similar during months 0–6 (lanadelumab, $377,326 vs berotralstat, $373,010), but decreased in months 7–12 ($319,967) and 13–18 ($283,241) of lanadelumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On-demand treatment/short-term prophylaxis costs were lower for lanadelumab across the three follow-up periods than for berotralstat during months 0–6 (berotralstat, $60,451; lanadelumab, months 0–6, $46,336, months 7–12, $37,578, months 13–18, $23,968).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“all dollar estimates were inflated to 2022 dollars using the medical care component of the Consumer Price Index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment costs over time with lanadelumab: US claims
“Fifty-four lanadelumab users were included; 25 (46%) had evidence of down titration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lanadelumab costs decreased from $316,724 to $269,861 to $246,919 in months 0-6, 7-12, and 13-18, respectively (p < .01); total HAE treatment costs decreased from $377,076 to $329,855 to $286,074 in months 0-6, 7-12, and 13-18, respectively (p < .01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Direct and indirect costs of on-demand treatment alone: US patient survey
“Per patient/year direct costs associated with modeled on-demand–only treatment totaled $363,795, with additional indirect socioeconomic costs of $52,576 per patient/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Medications comprise the largest component (62.5%) of modeled on-demand–only treatment, at an estimated $227,674 per patient per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second highest component cost was hospitalization for treatment of an HAE attack (22.1%), followed by ED visits (12.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual per-patient costs by attack severity before current prophylactic agents: US patient survey
“Total annual per-patient costs are estimated at $42,000 for the average HAE patient, with costs totaling $14,000 for patients with mild attacks, $27,000 for patients with moderate attacks, and $96,000 for patients with severe attacks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hospital costs account for 67% of direct medical costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents reported high rates of missed work, lost productivity, and lost income, contributing to indirect costs totaling $16,000 annually for the average patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Resource use after insurance delays or denials of prophylaxis
“A total of 70% of participants reported an increased frequency of angioedema attacks resulting from insurance delays or denials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-five percent of respondents reported more urgent care or emergency department visits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
On-demand drug costs per member before and after starting long-term prophylaxis: US commercial claims
| Population | Allowed cost per member, pre-LTP | Allowed cost per member, post-LTP | Change in allowed cost per member | Percent change |
|---|---|---|---|---|
| On-demand therapy experienced cohort (N = 29) | “$108,748” | “$61,390” | “-$47,358” | “-43.6%” |
Cost per attack treated on demand: Italian prospective cohort
“To explore treatment behaviours in a cohort of Italian patients with hereditary angioedema due to complement C1-inhibitor deficiency (C1-INH-HAE), and to estimate how effects and costs of treating attacks in routine practice differed across available on-demand treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost analyses and survival analyses using attack-level data collected prospectively for 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 133 of 167 patients (79.6%) reported 1508 attacks during the study period, with mean incidence of 11 attacks per patient per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only 78.9% of attacks were treated in contrast to current guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average cost per attack was €1183 (SD €789) resulting in €1.58 million healthcare costs during the observation period (€11 912 per patient per year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Icatibant was 54% more expensive than pdC1-INH, whereas age, sex and prophylactic treatment were not associated to higher or lower costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modeled cost per attack of on-demand treatments: US commercial payer decision model
“To estimate the cost-effectiveness of on-demand treatment for HAE attacks, a decision-tree model from the U.S. commercial payer perspective was developed using TreeAge Pro 2018 R1 release” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs are dated to 2019, either directly or by inflation using the medical-care inflation subset of the Consumer Price Index for All Urban Consumers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The base case model outputs show costs and calculated effectiveness per attack at $12,905 and 0.806 for rhC1-INH, $14,806 and 0.765 for icatibant, $14,668 and 0.769 for pdC1-INH, and $21,068 and 0.792 for ecallantide, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Emergency department and hospital use among users of intravenous C1 inhibitor: US claims
“The purpose of this retrospective study was to evaluate real-world treatment patterns of HAE-specific medications in the US and to assess their impact on healthcare resource utilization (HCRU).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis used IMS PharMetrics PlusTM database records (2006–2014) of patients with HAE, ≥1 insurance claim for an HAE-specific medication, and continuous insurance enrollment for ≥3 months following the first HAE prescription claim.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 631 total patients, 434 (68.8%) reported C1-INH(IV) use; 396 (62.8%) reported using ecallantide and/or icatibant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-eight (20.2%) of 336 C1-INH(IV) users eligible for the HCRU analysis were hospitalized at least once, and 191 (56.8%) visited the emergency department (ED).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by CSL Behring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Emergency department visits with hereditary angioedema: Nationwide Emergency Department Sample, 2006 to 2007
“We evaluated epidemiology, resource use, and discharge destinations of HAE (International Classification of Diseases, Version 9, clinical modification [ICD-9-CM] code 277.6) ED visits within the Nationwide Emergency Department Sample, part of Agency for Healthcare Research and Quality Healthcare Costs and Utilization Project, in 2006 and 2007.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In 2006-2007, there were 5040 ED visits with HAE, of which 2705 (53.7%) had HAE as the principal diagnosis (HAE-PD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two thousand fifty-nine (40.9%) resulted in a hospitalization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean HAE ED visits costs were $1479 (95% confidence interval, $1028-1929).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalizations and emergency department visits with hereditary angioedema: nationally representative inpatient and emergency department samples, 2007
“We examined hospitalizations and ED utilization for HAE and AE in two large nationally representative databases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We also used AHRQ-HCUP's 2007 Nationwide Emergency Department Sample (NEDS) to study annual rates of ED visits and subsequent hospitalizations with these conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were 1691 hospitalizations with HAE and 22,572 with AE (4.25 HAE and 57.08 AE cases/100,000 hospitalizations).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In aggregate, HAE and AE PD hospitalizations accrued 35,000 hospital days and hospital costs of $63 million.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were 2282 ED visits with HAE and 112,105 ED visits with AE (1.87 HAE and 91.64 AE cases/100,000 ED visits).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-five percent of HAE patients and 18.3% of AE patients required hospitalization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Attack-related medical visits and provider-administered on-demand treatment before and after berotralstat: US claims
“To evaluate all-cause, angioedema-related, and HAE attack–related medical visits and hospitalizations before and after initiation of berotralstat long-term prophylaxis (LTP) for patients with HAE in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This retrospective pre-post analysis used Komodo’s Healthcare Map claims data to identify patients who initiated berotralstat (December 2020 to December 2022).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study population included 260 patients treated with berotralstat (mean age = 39.7 years; 74.2% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When stratifying by type of care setting, rates of HAE attack–related IP episodes decreased by 60% (from 0.28 to 0.11 PPY, P < 0.001) and OP/ED episodes decreased by 50% (from 1.46 to 0.74 PPY, P < 0.001) after berotralstat initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following berotralstat initiation, the rates of on-demand medication administered by a provider decreased significantly by 32% (from 1.17 to 0.87 PPY, P = 0.002) among all patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Medical writing assistance was provided by Molly Gingrich, an employee of Groupe d’Analyze, Ltée, which received funding from BioCryst Pharmaceuticals for this study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medical care, activity loss, and missed work or school: European patient survey
“The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between attacks for patients and their caregivers over the past 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 164 patients had an attack in the past 6 months and were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most significant predictor of medical resource utilization was the severity of the last attack (OR 2.6; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who sought medical care during the last attack (23%), more than half utilized the emergency department.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The last attack prevented patients from their normal activities an average of 4–12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who were working or in school (n = 120), 72 provided work/school absenteeism data, resulting in an estimated 20 days missing from work/school on average per year; 51% (n = 84) indicated that HAE has hindered their career/educational advancement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was funded by ViroPharma SPRL-BVBA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Societal costs: Dutch patient survey
“Adult patients with HAE under treatment at the Dutch national center of reference completed a cross-sectional survey in 2021.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The response rate was 78% (69 of 88).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On average, total costs per year incurred €22,764, predominantly existing of HAE-medication costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total costs showed substantial variation between patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of hereditary angioedema on families
Income loss from work missed because of attacks
Caregiver productivity costs: US patient and caregiver survey
“For those respondents who indicated that they were either patients or caregivers or solely caregivers, the fact that they would no longer have to take time off work or could participate in the labor force, or be more productive while at work, accounted for $7630 (14.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver time, missed work, and children's missed school: multinational caregiver survey
“Using web-based surveys (July 2022‒February 2023), this international study (Argentina, Brazil, Colombia, Croatia, Denmark, Germany, Hungary, Ireland, Norway, Poland, Portugal, Romania, and Sweden) assessed the humanistic and psychosocial burden of caregivers (≥ 18 years old) of pediatric (< 18 years) and adult (≥ 18 years) patients with diagnosed HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 120 caregivers completed the surveys: 54 caregivers of pediatric patients (CoPs; mean age 40.6 years; 79.6% female) and 66 caregivers of adult patients (CoAs; mean age 42.7 years; 48.5% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the 4 weeks before completing the survey, caregivers of pediatric patients reported being absent from work for 2.6 ± 5.8 days (mean ± SD; median, 1.0 day), while the patients in their care missed 3.9 ± 6.2 days of school (mean ± SD; median, 2.0 days) over the same period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers reported providing care for 23.5 ± 11.8 (mean ± SD) days per month.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers of pediatric patients reported that their caregiving responsibilities limited their ability to plan their own lives in different ways, notably, to work full time (33.3%), to advance in their professional careers (25.9%), to pursue their personal interests or hobbies (25.9%), their freedom to travel or go on holiday (24.1%), and to relocate to another city or country (9.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the 4 weeks before the survey, caregivers (n = 33) reported missing 0.94 ± 1.39 (mean ± SD) days of work” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the patient’s most recent HAE attack, help provided by the caregivers primarily included providing emotional support (72.7%), spending time with the patient (68.2%), help with administering HAE medication (51.5%), and help with household chores (48.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was sponsored by Takeda Development Center Americas, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver absenteeism by attack frequency: European patient survey
“The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between attacks for patients and their caregivers over the past 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patient and caregiver absenteeism increased with attack severity and frequency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, the average numbers of missed days for patients were 2.2, 6.0, and 11.6 among patients with attacks less than once a month, at least once a month but less than once a week, and at least once a week, respectively (p = 0.128), and they reported that their caregivers missed 3.3, 3.6, and 10.1 days, respectively (p = 0.088).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver assistance with injectable on-demand treatment: US and UK interviews
“Interview participants included 25 individuals residing in either the UK (n = 8) or US (n = 17) (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight patients (57%) self-administered icatibant, while six (43%) required a parent or caregiver to administer, including two of the 10 adult patients (20%) and all adolescents (n = 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The three adolescents using C1INH had their injectable on-demand treatment administered in a health care setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some patients and caregivers described disruptions to leisure activities (n = 15) and having to leave work or school (n = 11), and these negative impacts were reported more frequently for adolescents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver health state utility during an attack: general public time trade-off valuation in England
“Members of the general public in England rated vignettes in TTO interviews, which included a visual analogue scale (VAS) component.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Qualitative interviews were undertaken to inform vignette development for the TTO study, including vignettes for abdominal, facial, hand and laryngeal attack health states, and an attack-free and caregiver state.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The caregiver rating was 0.762 (SD 0.303).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver tasks and burden: US caregiver survey
“In the United States, we conducted an online survey of adults caring for an individual with HAE to better understand their experiences with the disease and identify psychosocial impacts of providing care for a patient with HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty caregivers provided responses to the survey.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most caregivers were family members of the care recipient and many had HAE themselves.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers reported participating in a number of medical-related tasks and experiencing some burdens as a result of caring for a person with HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Genetic testing: cost and limited routine necessity
Medicare payment rates for complement antigen and functional assays
Functional C1 inhibitor assay as the single initial test and expected effect on diagnostic costs
“This approach involves performing only the C1-INH functional assay whenever this test is available and reliable, rather than following the traditional recommendation of conducting all 3 tests (C1-INH levels, C1-INH functional assay, and C4 level), potentially reducing diagnostic costs (Fig. 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The C1-INH antigenic assay is widely available, simple to perform, and generally accessible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Functional activity testing of C1-INH and genetic testing are both rarely available in low- and middle-income countries, and genetic testing is often expensive in high-income countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic testing for hereditary angioedema with normal C1 inhibitor and cascade family testing
“We recommend genetic testing for HAE-nC1-INH in patients for whom there is high clinical suspicion of HAE and who have normal C1-INH functional assay results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cascade screening refers to the process of sequentially testing close blood relatives, beginning with first-degree relatives and extending to siblings, parents, and children when a family member is found to be affected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This approach helps reduce costs, improves management of currently asymptomatic but affected individuals, and alleviates anxiety for unaffected family members.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost of sequential biochemical and genetic testing and sample transport
“Firstly, the use of a series of multiple tests from the initial C4 and C1-INH levels, followed by C1-INH function, and in equivocal cases or suspected HAE-nC1INH, genetic tests, is considerably costly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In regions lacking local laboratory capacity, samples must be shipped to external reference centres, incurring further costs and diagnostic delays [37].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C1-INH protein is labile in vitro; unless testing is performed within hours, samples require on-site centrifugation and storage at − 20 °C, necessitating an expensive cold chain for transport [38, 39].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of cascade family screening on hereditary angioedema-related costs: prospective screening program
“Prospective data on clinical, psychological, and HAE-related outcomes were collected at baseline and 1-year follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Potential HAE relatives were screened through the CFS approach.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 179 relatives, 53% were contactable, 67% of whom consented to screening.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-nine patients (46%) were newly given the diagnosis of HAE; half were symptomatic at baseline (52%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“By extrapolation, CFS led to a reduction of at least HK $1,200 (US $153) in HAE-related costs per patient per year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Screening using a greater than suggested C4 cutoff of 22.9 mg/dL yielded superior sensitivity (100%) and specificity (77%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic delay and its association with direct and indirect costs
Approaches to treatment
Current treatment options and standard of care
C1 esterase inhibitor concentrates
Plasma-derived C1 inhibitor: indication, dose, and self-administration
Plasma-derived C1 inhibitor: laryngeal attacks, thromboembolism, and infectious risk
Plasma-derived C1 inhibitor 20 IU/kg versus placebo: randomized clinical trial in the label
Plasma-derived C1 inhibitor 10 or 20 U/kg versus placebo: published randomized trial in 125 participants
“This was a randomized, double-blind, placebo-controlled study in 125 patients with type I or II hereditary angioedema.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median time to onset of relief was significantly shorter with C1 esterase inhibitor concentrate at a dose of 20 U/kg than with placebo (0.5 vs 1.5 hours; P = .0025), whereas with 10 U/kg, the time to onset of relief was only slightly shorter than with placebo (1.2 vs 1.5 hours; P = .2731).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with placebo, the reduction in time to onset of relief was greatest for severe attacks (0.5 vs 13.5 hours).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Plasma-derived C1 inhibitor for laryngeal attacks: open-label extension in the label
Recombinant human C1 inhibitor: indication, dose, redosing limit, and contraindication
Recombinant human C1 inhibitor 50 U/kg versus placebo: Study 1 in the label
“Seventy-five patients experiencing peripheral, abdominal, facial, and/or oropharyngeal laryngeal attacks were randomized (3:2) to rhC1INH (n = 44) or placebo (saline; n = 31).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median (95% confidence interval) time to beginning of symptom relief at the primary attack location was 90 minutes (61-150) in rhC1INH-treated patients vs 152 minutes (93, not estimable) in placebo-treated patients (P = .031) based on the TEQ” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, rhC1INH was safe and well tolerated; no thromboembolic events, anaphylaxis, or neutralizing antibodies were observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Recombinant human C1 inhibitor 50 or 100 U/kg versus saline: pooled analysis of two randomized trials
“Two similar independent, randomized, saline controlled, double-blind studies were conducted to evaluate the efficacy and safety of recombinant human C1-inhibitor (rhC1INH) as a treatment of acute angioedema attacks in patients with HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“rhC1INH at 100 (n = 29) and 50 (n = 12) U/kg body weight resulted in a significant reduction for both the primary endpoint time to the beginning of relief of symptoms compared with saline (n = 29): median, 66 (95% CI, 61-122) minutes, 122 (72-136) minutes, and 495 (245-520) minutes, P < .001 and P = .013, respectively” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Therapeutic failure occurred in 59% (17/29) of the saline group compared with 0% (0/12) of the 50 U/kg group and 10% (3/29) of the 100 U/kg group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intravenous C1 inhibitor as a first-line on-demand treatment: guideline recommendations
“Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is commercially available in 2 plasma-derived concentrates and 1 recombinant human product for intravenous administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that attacks are treated with either intravenous C1 inhibitor, ecallantide, or icatibant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For on-demand treatment, only the intravenous application of C1–INH is effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose rounding, half-life, and rabbit allergy: guideline statements
“When pdC-1INH is used, it should be administered at a dose of 20 IU/kg, rounded to the nearest 500 IU (as vials contain 500 IU) to minimize product waste.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“rC1-INH is produced through genetic engineering, and because it is secreted in the milk of transgenic rabbits, it is contraindicated in patients with a known allergy to rabbits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean plasma half-life of pdC1-INH is longer than 30 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It appears that differential glycosylation of Ruconest relative to the human protein decreases the plasma half-life to approximately 3 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma-derived C1 inhibitor in pregnancy and in children: guideline recommendations
“Plasma-derived C1-INH is considered safe and effective for on-demand treatment of HAE attacks during pregnancy, whereas all other drugs are off-label alternatives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For pregnant patients with HAE, we recommend first-line ODT with IV pdC1-INH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In neonates and infants with hereditary angioedema due to C1 inhibitor deficiency between birth and 2 years, we recommend the use of intravenous plasma‐derived C1 inhibitor concentrate as first‐line therapy for acute treatment of angioedema attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In children with hereditary angioedema due to C1 inhibitor deficiency aged between 2 and 12 years, we recommend the use of icatibant, intravenous plasma‐derived C1 inhibitor concentrate, or intravenous recombinant human C1 inhibitor as first‐line therapy for acute treatment of angioedema attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bradykinin b2 receptor antagonists
Icatibant: FDA-approved indication
Icatibant: dosing and maximum number of doses
Icatibant: self-administration
Icatibant: injection-site reactions
Icatibant: laryngeal attacks and interaction with ACE inhibitors
FAST-3: results as described in the FDA label
FAST-3: published primary and key secondary endpoints
“Cutaneous or abdominal attacks: icatibant significantly reduced median times (vs placebo) to 50% or more reduction in symptom severity (2.0 vs 19.8 hours; P < .001, primary endpoint), onset of primary symptom relief (1.5 vs 18.5 hours; P < .001, key secondary endpoint), or almost complete symptom relief (8.0 vs 36.0 hours; P = .012) and provided a shorter time to initial symptom relief (0.8 vs 3.5 hours; P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All icatibant-treated subjects experienced injection site reactions, but none reported clinically relevant changes in safety parameters or serious AEs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FAST-1 and FAST-2: icatibant compared with placebo and with tranexamic acid
“In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In FAST-1, the primary end point, the median time to clinically significant relief of the index symptom, was 2.5 hours in the icatibant group versus 4.6 hours in the placebo group (P = 0.14) (Table 2 and Fig. 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In FAST-2, the median time to clinically significant relief of the index symptom was 2.0 hours with icatibant versus 12.0 hours with tranexamic acid (P<0.001) (Table 2 and Fig. 1B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to almost complete relief of symptoms was 8.5 hours with icatibant versus 19.4 hours with placebo (P = 0.08) in FAST-1 (Table 2 and Fig. 2A) and 10.0 hours with icatibant versus 51.0 hours with tranexamic acid (P<0.001) in FAST-2 (Table 2 and Fig. 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Icatibant: treatment of recurrent attacks in open-label extensions
Generic icatibant: SAJAZIR indication and dosing
Generic icatibant: number of approved generic products
Icatibant: timing of treatment and attack duration in the Icatibant Outcome Survey
“The Icatibant Outcome Survey is an international, prospective, observational study for patients treated with icatibant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attack duration was significantly shorter in patients treated <1 hour of attack onset compared with those treated ≥1 hour (6.1 hours versus 16.8 hours [p<0.001]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Self-administrators were more likely to treat early and experience shorter attacks than those treated by a healthcare professional.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of attacks treated within 1 hour after attack onset was twice as high for self-administrators as for those who received HCP-administered icatibant (44% attacks versus 22% attacks, respectively; p = 0.001) (Figure 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Icatibant: guideline recommendation and redosing compared with C1 esterase inhibitor
“Both icatibant and C1-INH effectively reduce attack duration, with icatibant offering faster and more convenient self-administration but more frequently requiring a second dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deucrictibant: oral bradykinin B2 receptor antagonist in development
Plasma kallikrein inhibitors for on-demand treatment
Sebetralstat: FDA approval date
Sebetralstat: dosing and maximum daily dose
Sebetralstat: dose modification for CYP3A4 inhibitors and inducers and hepatic impairment
KONFIDENT: design and results as described in the FDA label
KONFIDENT: published primary and key secondary endpoints
“A total of 136 participants were assigned to one of six trial sequences, with 110 treating 264 attacks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The time to the beginning of symptom relief with the 300-mg dose and the 600-mg dose was faster than with placebo (P<0.001 and P = 0.001 for the two comparisons, respectively), with median times of 1.61 hours (interquartile range, 0.78 to 7.04), 1.79 hours (1.02 to 3.79), and 6.72 hours (1.34 to >12), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose, 49.5% with the 600-mg dose, and 27.4% with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov number, NCT05259917; EudraCT number, 2021-001226-21.).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sebetralstat: pooled analysis of the phase 2 and phase 3 trials
“377 attacks were treated: 87 with sebetralstat 300 mg; 151 with sebetralstat 600 mg; 139 with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median (interquartile range) time to treatment was 32.5 min (8.0–94.0).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median time to beginning of symptom relief was 1.6 h (0.8–7.0) and 1.8 h (1.0–4.3) with sebetralstat 300 mg and 600 mg, respectively, and 8.3 h (1.5 to >12) with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KONFIDENT-S: interim long-term safety and effectiveness
“This analysis evaluated long-term safety and effectiveness of sebetralstat in KONFIDENT-S (NCT05505916), an ongoing, 2-year, open-label extension study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At data cutoff (January 31, 2024), 84 participants (mean age: 35.9 years; 14.3% <18 years; 64.3% female) treated 640 attacks with sebetralstat (84% of total attacks); the median (interquartile range [IQR]) number of attacks per participant was 5 (2-8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median (IQR) time from attack onset to treatment was 9 (1-69) minutes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related TEAEs occurred in 8 participants (9.5%); none were serious.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to beginning of symptom relief (allowing for missing data entries between consecutive time points) was 1.68 (0.79-3.89) hours, to reduction in severity 6.57 (1.61 to >12) hours, and to complete attack resolution 21.02 (7.22 to >24) hours.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
KONFIDENT-S: breakthrough attacks in participants receiving long-term prophylaxis
“The safety and effectiveness of sebetralstat in participants receiving LTP are being assessed in the KONFIDENT-S open-label extension study (NCT05505916).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KONFIDENT-S: laryngeal and abdominal attacks
“This prespecified interim analysis evaluated the safety and effectiveness of sebetralstat in laryngeal and abdominal attacks in the ongoing, 2‐year, open‐label extension KONFIDENT‐S study (NCT05505916).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At data cutoff (Sep 14, 2024), 32 laryngeal (16 participants) and 533 abdominal only attacks (102 participants) were treated with sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median (IQR) time to treatment: 11.5 min (1.0–34.0) and 20.0 min (1.0–61.0) for laryngeal and abdominal attacks, respectively; time to beginning of symptom relief: 1.29 h (0.76–3.02) and 1.27 h (0.76–3.54); reduction in attack severity: 4.25 h (1.22 to > 12) and 3.52 h (1.26 to > 12); complete attack resolution: 12.69 h (5.11 to > 24) and 15.17 h (4.46 to > 24).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conventional on‐demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sebetralstat: guideline statement
“Sebetralstat, an oral plasma kallikrein inhibitor, was recently approved by the United States Food and Drug Administration (FDA) as an ODT for HAE, based on the findings of the KONFIDENT study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The only oral ODT available is sebetralstat and the dose is 2 300 mg tablets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ecallantide: boxed warning for anaphylaxis
Ecallantide: FDA-approved indication and dosing
Ecallantide: incidence of anaphylaxis in clinical studies
EDEMA4 and EDEMA3: design and results as described in the FDA label
Ecallantide compared with placebo: treatment outcome score at 4 hours in the trial funded by Dyax
“The median treatment outcome score at 4 hours was 50.0 in the ecallantide group and 0.0 in the placebo group (interquartile range [IQR], 0.0 to 100.0 in both groups; P=0.004).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated time to significant improvement was 165 minutes with ecallantide versus more than 240 minutes with placebo (P=0.14).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(Funded by Dyax; ClinicalTrials.gov number, NCT00262080.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ecallantide compared with placebo: change in mean symptom complex severity score at 4 hours
“Mean (SD) change from baseline in mean symptom complex severity score 4 hours after dosing was significantly greater with ecallantide use (-0.8 [0.6]) compared with placebo use (-0.4 [0.8]) (P = .01 comparing distributions).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The benefit of ecallantide was apparent within 2 hours after dosing and was maintained through 24 hours after dosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ecallantide: guideline position as a second-line option
“However, concerns about a 3%-4% risk of potentially serious hypersensitivity reactions, including anaphylaxis, led the manufacturer to withdraw its application in Europe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite this, it remains approved by the US Food and Drug Administration (FDA) for administration exclusively by healthcare providers in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest considering ecallantide as a second-line option for ODT for HAE attacks only when first-line therapies are not available or feasible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term prophylaxis
First-line long-term prophylaxis options: guideline recommendations
Subcutaneous plasma-derived C1 inhibitor: indication and dosing
Intravenous plasma-derived C1 inhibitor: indication and dosing
Lanadelumab: indication and dosing interval
Berotralstat: oral prophylaxis and dosing
Garadacimab: mechanism, population, and dosing
Donidalorsen: indication, mechanism, and dosing
Lanadelumab and berotralstat: guideline summary of efficacy
“Lanadelumab, a fully human monoclonal antibody directed against plasma kallikrein, reduces the risk of attacks in the context of LTP, with a low risk of adverse events and a positive impact on QoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reported attack rates with this drug are less than 0.3 per month with biweekly dosing, and over 95% of treatment-emergent adverse events are non-serious.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Berotralstat, an oral plasma kallikrein inhibitor, demonstrated efficacy in a pivotal trial, achieving a ∼50% reduction in attack rate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients should be aware of delayed onset of action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attenuated androgens: second-line prophylaxis
“We recommend the use of androgens only as second-line long-term prophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest IV C1-INH, attenuated androgens (at the lowest effective dose, preferably not exceeding 200 mg per day), or antifibrinolytics as second-line options for LTP in patients for whom first-line therapies are not available, not feasible, or not tolerated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Attenuated androgens are strongly associated with virilization in women, dyslipidemia, and hepatotoxicity, with an increased risk of hepatic neoplasms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deucrictibant extended-release tablet for prophylaxis: CHAPTER-3 phase 3 results (investigational)
Attacks during prophylaxis and continued access to on-demand treatment: guideline statements
“Attacks can still occur even in patients under LTP, and on-demand medication must remain available to them.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients have access to ODT, even while receiving LTP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attacks and on-demand treatment use during prophylaxis: systematic review of 45 studies
“Forty-five primary studies met the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In phase 3 trials, attack-free rates were 40% for subcutaneous pdC1INH 60 IU/kg twice weekly at 16 weeks, and 44% for lanadelumab 300 mg every second week at 6 months (77% during steady-state [days 70–182]); there was no difference in attack-free rate for berotralstat 150 mg versus placebo at 24 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Laryngeal attacks accounted for 2%-7% of all attacks in observational and interventional studies, regardless of the LTP agent received.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On-demand therapy was used in 49%-94% of attacks occurring in the presence of LTP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Persistence, switching, and on-demand use after starting prophylaxis: US claims
“This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even with use of LTP, on-demand treatment utilization remained present for over two-thirds of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
On-demand prescriptions after starting subcutaneous prophylaxis: US claims
“Study population included 196 patients (C1-INH-SC: N=65; lanadelumab: N=131); mean age was 39 years and 69% were female.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annualized number of ODT prescriptions was 3.8 (3.6–4.1) per patient” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
On-demand rescue medication during intravenous C1 inhibitor prophylaxis: US claims
“There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
On-demand dispensing during lanadelumab or berotralstat prophylaxis: Swedish national register
“Among patients with ≥12 months on modern LTP (n=69) who had at least one ODT dispensation event during their most recent 12 months of treatment (n=46/59 for lanadelumab; n=8/9 for berotralstat), the mean number of ODT packages dispensed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in addition to emergency stock ODT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“was 4.3 per patient on lanadelumab and 6.5 per patient on berotralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 22% (n=15/69) of patients receiving modern LTP did not dispense ODT medication during their most recent 12-months of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Breakthrough attack rate during prophylaxis: KONFIDENT-S interim analysis
“As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fresh frozen plasma and other measures
Solvent detergent-treated plasma and fresh frozen plasma: third-line on-demand treatment
“If IV C1-INH, icatibant, sebetralstat or ecallantide is unavailable, solvent detergent-treated plasma (SDP) or FFP may be considered, provided that a safe and reliable supply of these blood products can be ensured.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend SDP/FFP as third-line treatment, with SDP preferred over FFP if available due to a lower risk of viral transmission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Where these first-line therapies are not available, attacks should be treated with solvent detergent-treated plasma (SDP). If SDP is not available, attacks should be treated with fresh frozen plasma (FFP), where safe supply is available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fresh frozen plasma: US guideline fallback and risk of worsening
Frozen plasma: International/Canadian guideline recommendation and access delays
Fresh frozen or solvent detergent plasma in children: pediatric guideline
“We suggest, when none of the first‐line treatment options are available, using fresh frozen or solvent detergent plasma for acute treatment of angioedema attacks involving the upper airway, gastrointestinal tract, neck, or face in pediatric patients with hereditary angioedema due to C1 inhibitor deficiency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These agents are associated with a risk of anaphylactic reaction and transmission of blood‐borne infections” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antifibrinolytics and attenuated androgens: not recommended for acute attacks
“Using antifibrinolytics (such as tranexamic acid) or attenuated androgens (such as danazol) for ODT is discouraged because of a lack of benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antihistamines, corticosteroids, and epinephrine: ineffective for bradykinin-mediated attacks
Supportive care when effective on-demand treatment is not available
Upper airway involvement and airway management: guideline recommendations
“We recommend that in the case of upper airway swelling, ODT should be given as early as possible, and patients should seek emergency care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that airway interventions (intubation, cricothyroidotomy, or tracheotomy) be promptly considered during the initial evaluation of patients presenting with signs of upper airway involvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If intubation is indicated but proves difficult or impossible, an emergency cricothyrotomy or tracheotomy should be performed without delay.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that intubation or surgical airway intervention is considered early in progressive upper airway edema.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that upper airway, facial, and neck edema should always be treated. In case of upper airway edema, pediatric patients with hereditary angioedema should also have an emergency referral to a hospital where airway management is available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary: injectable administration, treatment delay, and untreated attacks
The approved on-demand C1 inhibitors are given intravenously (plasma-derived C1 inhibitor at 20 IU/kg by intravenous injection; recombinant C1 inhibitor at 50 U/kg as a slow intravenous injection), icatibant is given as a 30 mg subcutaneous injection, and ecallantide as three 10 mg subcutaneous injections; sebetralstat is taken orally. The sponsor states that most on-demand therapies are administered by injection and that this burden causes people to delay or forgo treatment of their attacks. In interviews with 25 US and UK patients and caregivers, participants cited fear of needles, portability, and complexity of administration as reasons for delaying or forgoing injectable on-demand treatment; 80% reported not treating every attack, and some adult and all adolescent patients reported needing assistance with administration.
In a survey of 107 respondents, 57% did not treat all attacks, only 14% treated attacks immediately, and the mean time to treatment was 2.4 h; respondents who waited 1 h or longer cited the attack not being considered severe enough to treat (86.9%), not having on-demand treatment with them (59%), and the treatment being too painful (32.8%), and 32.7% of respondents experienced the return of an attack after initial treatment. Another report of 107 US survey respondents found that 63.6% did not carry on-demand treatment at all times when away from home, 86% reported delaying on-demand treatment, and an average of 20% of attacks were untreated (24% among on-demand-only patients and 15% among prophylaxis patients). In a further US survey, of the 67% of the treated cohort (n = 94) who reported treating early, only 26% administered on-demand treatment in less than 1 hour, 79% reported treatment-related anxiety that correlated with treatment delay, and untreated attacks lasted a mean of 2.3 days. In a survey funded by KalVista Pharmaceuticals, the mean delay from attack onset to on-demand treatment was 2.9 h (SD 2.7), 10% treated within 1 h, 13% sought hospital or emergency services for administration during the last treated attack, 51% required caregiver support, and adolescents and users of intravenous on-demand treatment were more likely to delay treatment because of administration-related barriers. Patients using long-term prophylaxis reported treating a mean of 84.8% of their attacks, compared with 75.6% for patients using on-demand treatment only. In the Icatibant Outcome Survey, 44% of attacks in self-administrators and 22% in patients receiving icatibant from a health care professional were treated within 1 hour of onset, and attack duration was 6.1 hours in patients treated within 1 hour of onset and 16.8 hours in those treated at 1 hour or later.
Summary: adverse reactions, administration by health care professionals, and restrictions of use
Injection site reactions occurred in 97% of patients receiving icatibant in clinical trials. In FDA Adverse Event Reporting System data for the parenteral on-demand therapies, the highest reported rates of administration-site reactions were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year), and access-site complications or malfunctions were reported only for recombinant C1 inhibitor (9.5 per year); these rates are not exposure adjusted. Serious arterial and venous thromboembolic events have been reported with plasma-derived C1 esterase inhibitor products, and plasma-derived C1 inhibitor may carry a risk of transmitting infectious agents. Recombinant C1 inhibitor is contraindicated in patients with allergy to rabbits or rabbit-derived products, and its effectiveness was not established in laryngeal attacks. Anaphylaxis occurred in 10 of 255 participants (4%) treated with ecallantide in clinical studies, and ecallantide is administered only by a health care professional; a guideline suggests it only as a second-line option. Icatibant is indicated for adults 18 years of age and older. Patients who self-administer plasma-derived C1 inhibitor or icatibant for a laryngeal attack are advised to seek medical attention in a health care facility. Plasma products used when HAE-specific treatment is unavailable are available only for in-hospital use, with delays of sometimes up to 24 h in obtaining them.
Users of intravenous C1 inhibitor had higher crude rates of hospitalization (20% vs 6%) and emergency department visits (57% vs 43%) than patients not using an HAE medication requiring intravenous access, and 18 (5.4%) had a central venous access device. Severe laryngeal attacks were not treated in the sebetralstat trial KONFIDENT, and a guideline states that long-term data from extension studies and real-world evidence for sebetralstat are still lacking.
Summary: repeat dosing and rescue medication
Repeat treatment during a single attack is approved for icatibant (up to 3 doses within 24 hours at intervals of at least 6 hours) and for ecallantide and recombinant C1 inhibitor (up to 2 doses within 24 hours); sebetralstat allows a second 600 mg dose at least 3 hours after the first, up to 1,200 mg in any 24-hour period. A guideline states that icatibant more frequently requires a second dose than C1 inhibitor. In Trial 1 of the icatibant label, 3 of 43 participants (7%) treated with icatibant used additional rescue medication, compared with 18 of 45 (40%) with placebo, and in a further analysis in the label, 93% of 987 attacks were treated with a single dose. In the sebetralstat label, 38% of participants in the 600 mg group administered a second dose within 12 hours. Recombinant C1 inhibitor was given as rescue medication to 5 of 44 participants (11%) randomized to it and 13 of 31 (42%) randomized to placebo, and 5 of 170 attacks (3%) in the open-label phase received a second dose. In EDEMA4, 16 of 48 participants (33%) treated with ecallantide and 24 of 48 (50%) given placebo required medical intervention for unresolved symptoms within 24 hours. In the KONFIDENT-S extension, conventional on-demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks treated with sebetralstat.
Summary: attacks and on-demand treatment use during long-term prophylaxis
Guidelines state that long-term prophylaxis does not completely eliminate the risk of attacks and recommend that patients receiving it keep access to on-demand treatment, with at least two doses available. A review of 45 primary studies reported attack-free rates in phase 3 trials of 40% for subcutaneous plasma-derived C1 inhibitor at 16 weeks and 44% for lanadelumab every second week at 6 months, with no difference in attack-free rate for berotralstat versus placebo at 24 weeks; laryngeal attacks accounted for 2% to 7% of attacks, and on-demand therapy was used in 49% to 94% of attacks occurring during prophylaxis. In one claims analysis, on-demand treatment use remained present for over two-thirds of patients after starting prophylaxis, and 55% had refill gaps, discontinued, or switched prophylaxis within a year. Among 196 patients on subcutaneous prophylaxis in another analysis, the mean annualized number of on-demand prescriptions was 3.8 per patient, and in a third, on-demand rescue medication was used during 53% (163/306) of episodes of intravenous C1 inhibitor prophylaxis. In another cohort, patients with at least 12 months on lanadelumab or berotralstat who had an on-demand dispensation were dispensed a mean of 4.3 and 6.5 packages, respectively, in their most recent 12 months, and 22% (15/69) dispensed none. In the KONFIDENT-S extension, 35 participants receiving prophylaxis experienced a mean of 1.7 attacks per month (SD 1.5). A guideline states that only about 50% of patients currently receive long-term prophylaxis, even in high-income countries, and that the higher costs of newer drugs limit their availability.
Parenteral administration and treatment delay: sponsor statement
Burden of injectable on-demand treatment: patient and caregiver interviews
“The 25 study participants from the US and UK (17 patients; 8 caregivers), who completed the interview, highlighted emotional and logistical reasons for delaying or forgoing injectable on-demand treatment, including fear of needles, portability, and complexity of administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although indicated for self-administration, some adult and all adolescent patients reported needing assistance with administration of their injectable on-demand treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Untreated attacks, delayed treatment, and attack recurrence: US survey of 107 participants
“A total of 107 out of 155 participants completed the survey (mean age = 41 years; 80.4% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The survey revealed that 57% of respondents did not treat all HAE attacks, and only 14% treated attacks immediately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Delays in treatment were common, with a mean time to treatment of 2.4 h, and younger patients were less likely to carry on-demand treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most important reasons cited by those who waited 1 h or longer to initiate on-demand treatment were the attack not being considered severe enough to treat (86.9%), not having on-demand treatment with them (59%), and their on-demand treatment being too painful (32.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, 32.7% of respondents experienced the return of an HAE attack after initial treatment, with those delaying treatment more likely to experience recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This work was sponsored by KalVista Pharmaceuticals, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Share of attacks treated by prophylaxis status: US survey
“Patients using LTP reported treating a mean ± standard deviation 84.8% ± 23.8% of their HAE attacks compared with a mean ± standard deviation 75.6% ± 27.5% for patients with on-demand only treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time to treatment, treatment-related anxiety, and untreated attacks: US survey
“In the Treated Cohort (n = 94), of the 67% who reported treating their attack early, only 26% administered OD in less than 1 hour.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, 79% (n = 74) reported treatment-related anxiety, which correlated with treatment delay.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the Untreated Cohort (n = 20), 50% of the respondents describing their last untreated attack as mild experienced progression to moderate or severe and 25% reported spread to another site including the larynx and face.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Untreated attacks lasted a mean of 2.3 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment delays, emergency care, and administration barriers: Italian survey
“For the respondents' last treated attack, 13% sought hospital/emergency services for OD administration, and 51% required caregiver support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respondents reported a mean (SD) delay of 2.9 (2.7) h from attack onset to OD, with 10% treating < 1 h, 24% treating 1 to < 2 h, 51% treating 2 to < 5 h, and 16% treating ≥ 5 h from onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, adolescents and those receiving intravenously administered OD were more likely to delay treatment because of administration‐related barriers than adults and those receiving subcutaneously administered OD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Funding: This study was funded by KalVista Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration-site reactions with parenteral on-demand treatments: FDA adverse event reports
“The highest reported rates of administration-site ADRs per year were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“RhC1-INH was the only drug for which access-site complications and/or malfunctions were reported (9.5 per year).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It should be noted that ADR rates are not exposure adjusted and are based on spontaneous reporting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Venous access devices, hospitalization, and emergency department visits with intravenous C1 inhibitor: US claims
“Users of C1-INH(IV) (n = 336; 64.5%) had higher crude rates of hospitalization (20% vs 6%) and ED visits (57% vs 43%) compared with patients not using an HAE medication requiring IV access (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eighteen patients (5.4%) had a central venous access device (CVAD); of these, 5 (27.7%) required hospitalization and 14 (77.7%) had an ED visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Emergency department visits for hereditary angioedema: US national sample, 2006 to 2007
“In 2006-2007, there were 5040 ED visits with HAE, of which 2705 (53.7%) had HAE as the principal diagnosis (HAE-PD).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two thousand fifty-nine (40.9%) resulted in a hospitalization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Repeat dosing limits and second-dose frequency with existing on-demand agents
“Both icatibant and C1-INH effectively reduce attack duration, with icatibant offering faster and more convenient self-administration but more frequently requiring a second dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ecallantide administration restriction and limited long-term data for sebetralstat: guideline statements
“Due to the risk of hypersensitivity reactions, ecallantide must be administered only under the supervision of healthcare personnel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events are limited to headache, nevertheless, long-term data from extension studies and RWE are still lacking, precluding appropriate comparisons between this novel agent and existing first-line ODT options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uptake of prophylaxis and cost as a barrier to access
“Nevertheless, even with recent advances, LTP is still not the standard of care, even in high-income countries, with only about 50% of patients currently receiving it.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite their greater effectiveness, newer drugs are associated with higher costs that clearly limit their availability, particularly in low- and middle-income countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary: guideline recommendations for on-demand treatment
The guideline by Vázquez et al. recognizes four types of on-demand treatment as effective (intravenous C1-INH, icatibant, sebetralstat, and ecallantide), recommends intravenous C1-INH, icatibant, or sebetralstat as first-line, suggests ecallantide as a second-line option only when first-line therapies are not available or feasible, and recommends solvent detergent-treated plasma or fresh frozen plasma as third-line; it states that direct comparisons among these options are limited, and recommends intravenous plasma-derived C1-INH as first-line for pregnant patients. The guideline by Betschel et al. lists ecallantide, icatibant, intravenous C1INH, and sebetralstat as effective therapies, discussed “without implying any hierarchy of preference”, and states that access to another effective acute treatment is crucial given variation in patient response. A pediatric guideline recommends icatibant, intravenous plasma-derived C1-INH, or recombinant C1-INH as first-line acute treatment for children aged 2 to 12 years, and ecallantide, icatibant, either intravenous C1-INH, or sebetralstat for adolescents aged 12 years or older.
The guidelines recommend that all attacks be considered for on-demand treatment and treated as early as possible, that every patient have medication for at least 2 attacks, kept at home, and that patients carry on-demand medication at all times; the US HAEA Medical Advisory Board recommends that all patients with HAE due to C1-INH deficiency have access to at least two standard doses. Upper airway swelling calls for on-demand treatment as early as possible and emergency care, and all patients with laryngeal edema are to be assessed in the emergency department even after self-therapy. The Vázquez et al. guideline states that the only oral on-demand treatment available is sebetralstat and that long-term data for it are still lacking. Deucrictibant appears in none of the guidelines' lists of recommended agents; the Vázquez et al. guideline states that preliminary results have demonstrated its efficacy for treating attacks, and the pediatric guideline notes that RAPIDe-3 is evaluating it in adolescent and adult patients.
Summary: anticipated use of an oral on-demand option and care setting
Deucrictibant is described as the first and only orally administered bradykinin B2 receptor antagonist investigated for on-demand treatment of HAE attacks. In RAPIDe-3, participants self-administered the study drug during or immediately after a qualification call with the investigator, and in Part 2 of RAPIDe-1 participants self-administered it at home. Adolescents with laryngeal attacks of any severity and adults with severe laryngeal attacks were instructed to take their conventional on-demand therapy instead of the study drug and to seek medical care urgently. One publication notes that the recommendation to treat all attacks as early as possible shaped the design of recent trials, including those of sebetralstat and deucrictibant.
The trial investigators state that an efficacious oral on-demand option with a favourable safety profile “could address key unmet needs”, and that further studies of patient preferences, including number of pills administered per dose, are warranted. A guideline states that HAE is well suited to self-treatment, especially by oral administration, and that injectable therapies can pose barriers such as needle phobia, poor venous access, or impaired dexterity; ecallantide must be administered under the supervision of health care personnel. The sponsor intends to file for approval of and commercialize deucrictibant immediate-release capsules as an on-demand treatment for HAE attacks through its own commercial infrastructure, states that an oral on-demand treatment could decrease the burden of therapy through easier administration, portability, and discretion, and states its belief that deucrictibant could become standard of care for on-demand treatment. The sponsor is also preparing an NDA for the extended-release tablet for prophylaxis, which reduced the mean monthly attack rate by 83% in CHAPTER-3, with submission planned for 1H2027; these data concern the extended-release tablet.
Summary: patient and physician preference
In a study in which Pharvaris participated in the interpretation of the data, 225 physicians completed patient record forms for 1131 patients and 279 patients completed a questionnaire; 84% of patients in the patient-reported group indicated that, given the choice, they would prefer to take their on-demand treatment by mouth. The top physician-reported unmet needs of on-demand treatment were a different route of administration (320/817 [39%]), discomfort upon administration (112/817 [14%]), and injection site reactions (111/817 [14%]); patients most often reported not liking injections and experiencing pain, bruising, or burning with injections (42/227 [19%] each), followed by not liking to inject medications in public places (38/227 [17%]). In interviews with 25 US and UK patients and caregivers, in a study supported by KalVista Pharmaceuticals, all participants expressed interest in an oral on-demand treatment, and 8 indicated that they would treat attacks earlier with one; more than half regarded the need to swallow a tablet as a potential disadvantage during a throat or facial attack, and some were concerned about how quickly an oral tablet would begin to work.
Summary: payer criteria and quantity limits
Published payer policies refer to generic icatibant in their criteria for on-demand treatment, including sebetralstat (Ekterly). Cigna requires prior authorization, with coverage for patients aged 12 to under 18 years, patients who have previously treated an attack with Ekterly, or patients who have tried generic icatibant; its quantity limits allow treatment of 4 attacks per 28 days at the maximum Ekterly dose, with an override for an additional 4 attacks each month and a one-time override of 16 additional tablets. Univera Healthcare requires documentation of therapeutic failure, severe intolerance, or a contraindication to generic icatibant for Ekterly requests in patients 18 years of age and older, lists a quantity limit of 4 tablets per 30 days, authorizes one acute HAE medication at one time, and does not approve requests for quantities in excess of its limits. A Regence policy requires documentation that generic icatibant and either Berinert or Ruconest have been ineffective, not tolerated, or contraindicated, authorizes acute treatments in a quantity sufficient for three attacks per month, or four to six attacks per month when its criteria are met (including, for HAE types I and II, evaluation for prophylactic therapy), and states that “Generic icatibant is the lowest cost of all available options.”
First-line on-demand treatment options: WAO guideline
“We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct comparisons among these options are limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest considering ecallantide as a second-line option for ODT for HAE attacks only when first-line therapies are not available or feasible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend SDP/FFP as third-line treatment, with SDP preferred over FFP if available due to a lower risk of viral transmission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral on-demand treatment in the WAO guideline
“The only oral ODT available is sebetralstat and the dose is 2 300 mg tablets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sebetralstat, an oral plasma kallikrein inhibitor, was recently approved by the United States Food and Drug Administration (FDA) as an ODT for HAE, based on the findings of the KONFIDENT study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“long-term data from extension studies and RWE are still lacking, precluding appropriate comparisons between this novel agent and existing first-line ODT options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effective acute therapies: International/Canadian guideline
Treatment of every attack as early as possible: guideline recommendations
“We recommend that ODT be considered for all HAE attacks, which is mandatory when upper airway involvement is detected, and should be instituted as early as possible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that all attacks are considered for on-demand treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that attacks are treated as early as possible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
On-demand medication at home for at least two attacks: guideline recommendations
“We recommend that every patient, even if asymptomatic, must have ODT available at home because the risk of a serious attack is unpredictable and persists throughout their lifetime.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HAE attacks can follow an unpredictable clinical course, rebound is possible, and multiple attacks can appear in quick succession. Therefore, patients should always have enough medication available to treat at least 2 acute attacks at home.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that all patients have sufficient medication for on-demand treatment of at least two attacks and carry on-demand medication at all times.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with frequent attacks, the time it takes to obtain more on-demand medication should be taken into consideration in the provision of treatment, so that they never run out of on-demand medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pediatric guideline: first-line acute treatment by age
“In children with hereditary angioedema due to C1 inhibitor deficiency aged between 2 and 12 years, we recommend the use of icatibant, intravenous plasma‐derived C1 inhibitor concentrate, or intravenous recombinant human C1 inhibitor as first‐line therapy for acute treatment of angioedema attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adolescents with hereditary angioedema due to C1 inhibitor deficiency aged 12 years or older, we recommend the use of ecallantide, icatibant, intravenous plasma‐derived C1 inhibitor concentrate, intravenous recombinant human C1 inhibitor, or sebetralstat as first‐line therapy for acute treatment of angioedema attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend acute treatment of angioedema attacks in pediatric patients with hereditary angioedema as early as possible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 3 trial instructions for laryngeal attacks
Care setting: self-administration at home in deucrictibant trials
Care setting: agents requiring administration by health care personnel
Oral administration and self-treatment: International/Canadian guideline
Evolution of on-demand treatment guidelines and trial design
“In 2013, the US Hereditary Angioedema Association guidelines recommended that all attacks, irrespective of location or severity, be considered for treatment as early as possible after onset to minimize morbidity and mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This approach remains the cornerstone of current treatment guidelines and has shaped the design of recent clinical trials, such as those for the investigational agents, oral plasma kallikrein inhibitor sebetralstat and oral bradykinin B2 receptor antagonist deucrictibant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deucrictibant in guideline and review discussion
“Two distinct formulations are being investigated: immediate-release capsule (previously referred to as PHVS416) and extended-release tablet (previously referred to as PHVS719).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Preliminary study results on the use of deucrictibant for the treatment of HAE attacks have demonstrated its efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RAPIDe‐3 is evaluating an oral BDKRB2 antagonist (deucrictibant) in adolescent and adult patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Published and ongoing clinical studies demonstrate favorable safety, tolerability, and efficacy profiles for both LTP and ODT, offering a convenient oral alternative that may reduce treatment burden and improve patient quality of life.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Trial investigators' statement on the role of an oral on-demand option
Company statements on intended positioning
Company statement: deucrictibant XR prophylaxis development
Patient and physician survey: preference for oral on-demand treatment, Pharvaris-supported analysis
Qualitative interviews: perceptions of an oral on-demand treatment
“All participants expressed interest in an oral on-demand treatment when asked directly, with some suggesting this spontaneously during interviews while discussing the difficulties with their current injectable treatments. Participants indicated that if they had oral on-demand treatment available, they would treat attacks earlier (n = 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More than half of participants believed the need to swallow a tablet was a potential disadvantage if they were having a throat or facial attack.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some participants expressed concerns about the speed at which an oral tablet would begin to work, as a pill needs to dissolve to enter the blood stream, unlike injectable medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Case series: reasons for switching to an oral on-demand treatment
Payer step therapy and quantity limits for oral on-demand treatment: Regence
Payer quantity limits for oral on-demand treatment: Cigna drug quantity management
Payer preferred product criteria for oral on-demand treatment: Cigna prior authorization
Payer step therapy and quantity limits for on-demand treatments: Univera Healthcare
Heterogeneity of treatment effect
RAPIDe-3 subgroups: participants with at least one study drug-treated attack
RAPIDe-3 subgroups: hereditary angioedema with normal C1 inhibitor
RAPIDe-3 regional subgroups: North America and Europe/Rest of World, all participants with treated attacks
RAPIDe-3 regional subgroups: median times to onset of symptom relief, reduction in attack severity, and complete resolution
| Outcome and region | Deucrictibant IR | Placebo |
|---|---|---|
| Onset of symptom relief, North America | “1.20 hours (95% CI: 0.84, 1.84)” | “6.55 hours (95% CI: 1.88, >12)” |
| Onset of symptom relief, Europe/Rest of World | “1.28 hours (95% CI: 1.04, 1.41)” | “>12 hours (95% CI: 5.74, >12)” |
| Reduction in attack severity, North America | “2.43 hours (95% CI: 1.03, 5.12)” | “>12 hours (95% CI: 2.65, >12)” |
| Reduction in attack severity, Europe/Rest of World | “2.53 hours (95% CI: 1.70, 2.98)” | “>12 hours (95% CI: 12.10, >12)” |
| Complete symptom resolution, North America | “11.61 hours (95% CI: 2.94, 26.14)” | “>48 hours (95% CI: 17.21, >48)” |
| Complete symptom resolution, Europe/Rest of World | “12.04 hours (95% CI: 8.64, 21.79)” | “>48 hours (95% CI: >48, >48)” |
RAPIDe-1 attack location: cutaneous and abdominal attacks
Sebetralstat pooled phase 2 and 3 trials: subgroups by location, severity, age, sex, region, and regimen
“In the subgroup analysis, results favoring sebetralstat versus placebo were generally consistent when analyzed by pooled primary HAE attack location (mucosal, abdominal only, or subcutaneous), baseline attack severity, age, sex, geographic region, and treatment regimen (Fig. 3). Of note, HAE attacks with a baseline severity of “Severe” or “Very Severe” more strongly favored sebetralstat over placebo in terms of time to beginning of symptom relief compared with attacks with a baseline severity of “Mild” or “Moderate”, although results should be interpreted with caution due to the wide confidence intervals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For HAE attacks rated “Severe” or “Very Severe” at baseline, conventional medication was used for 2 of 14 attacks (14.3%) treated with sebetralstat 300 mg, 3 of 20 attacks (15.0%) treated with sebetralstat 600 mg, and 6 of 14 attacks (42.9%) treated with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analyses are exploratory in nature and not adjusted for multiplicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sebetralstat open-label extension: attacks during long-term prophylaxis by severity, location, and age
“In subgroup analyses by attack severity at the time of sebetralstat administration, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 1.8 (1.0-7.0) hours, 1.3 (0.8-3.5) hours, and 1.3 (0.5-1.8) hours for mild, moderate, and severe/very severe attacks, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analyses by attack location showed median (IQR) times to beginning of symptom relief in participants receiving any LTP agent of 1.3 (0.7-2.2) hours, 1.4 (0.9-4.1) hours, 1.0 (0.5-2.2), and 1.7 (1.2-6.0) hours for attacks with mucosal involvement, attacks with laryngeal involvement, attacks limited to the abdomen, and attacks limited to subcutaneous tissues, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In subgroup analyses by age, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 0.7 (0.3-1.4) hours and 1.7 (1.1-5.5) hours for participants aged <18 years (n = 5) and participants aged ≥18 years (n = 30), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the study was not designed or powered to evaluate differences in the effectiveness of sebetralstat by the specific LTP agent received or differences between subgroups; these data are reported to offer a preliminary clinical overview.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Icatibant: time to treatment, attack location, and severity in the Icatibant Outcome Survey
“Attack duration was significantly shorter in patients treated <1 hour of attack onset compared with those treated ≥1 hour (6.1 hours versus 16.8 hours [p<0.001]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Self-administrators were more likely to treat early and experience shorter attacks than those treated by a healthcare professional.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both abdominal and cutaneous attacks were found to be of shorter total duration when treated early. Additionally, early treatment resulted in significant reductions in attack duration regardless of attack severity (Tables 4 and 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ecallantide: response by time to treatment in the EDEMA trials
“Change from baseline in MSCS score and TOS at 4 hours revealed significantly better response to ecallantide versus placebo for patients treated >2-4 (n = 46; p = 0.002; p = 0.003) or >4-6 (n = 47; p = 0.044; p = 0.043) hours after symptom onset. Fewer patients were treated within 2 hours of symptom onset; for these patients (n = 10; p = 0.752; p = 0.422) treatment did not achieve statistical significance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Icatibant and plasma-derived C1 inhibitor: attack site and time to treatment in a prospective cohort
“Attack severity and attack site were not found to be associated with different remission rates, with the only exception for laryngeal attacks (HR 1.44, 95% CI 1.07 to 1.95).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, shorter time to treatment was associated with a small (2%) but significant positive effect on remission rates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
US HAEA Medical Advisory Board guidelines: on-demand medication access
On-demand treatment during long-term prophylaxis: guideline recommendations
“We recommend that patients have access to ODT, even while receiving LTP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients or their caregivers are advised to always carry enough medication to treat at least 2 HAE attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-administration and home therapy
“Self-administration and home therapy are available for all C1-INH products, icatibant, berotralstat, sebetralstat, donidalorsen, garadacimab, and lanadelumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients and their caregivers be educated in how to administer ODT, including self-administration with all available formulations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring of disease control with validated instruments
“We recommend that all patients with HAE use validated instruments to assess disease activity, severity, disease control, treatment efficacy, and QoL, and that they undergo regular reassessments to ensure optimal therapeutic management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend evaluating efficacy and safety of the long‐term prophylactic agent in pediatric patients with hereditary angioedema due to C1 inhibitor deficiency at least three and six months after initiation, then at least annually.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Individualized action plans: guideline recommendations
“We recommend that all patients have an action plan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It should include an effective emergency (on-demand) treatment plan, with clear instructions on how to best use medications to treat HAE attacks. Patients should carry on-demand medication and an HAE identification card with instructions on how to manage an HAE attack. Patients on long-term prophylaxis also require an action plan and available therapy for on-demand use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend creating an action plan for acute treatment of angioedema attacks in pediatric patients with hereditary angioedema, considering availability of medications and patient/caregiver preferences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HAE management plan elements: US HAEA
Home therapy training: guideline recommendations
“We recommend that all patients who are provided with on-demand treatment licensed for self-administration should be taught to self-administer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Home therapy decreases the severity and duration of HAE attacks, reduces morbidity and disability, and can improve quality of life and productivity. In addition, the cost of care is reduced considerably using home and self-therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Education programs and call centers
“Educational programs focused on the self-administration of on-demand medications, along with national call centers that provide support to patients during acute attacks, have a significant impact on outcomes. Evidence shows that these initiatives can reduce the need for emergency department visits and hospitalizations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comprehensive care and HAE treatment centers
“We recommend that HAE-specific comprehensive, integrated care is available for all patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients are treated by a specialist with specific expertise in managing HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Carrying on-demand treatment away from home: patient survey
“Most patients (63.6%) reported that they did not carry on-demand treatment at all times when away from home. The most common reason for not carrying on-demand treatment when away from home was ‘prefer to treat at home’ (72.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Payer involvement of HAE specialists: International/Canadian guideline
Payer prescriber requirements for on-demand treatments
Payer benefit channel: pharmacy and medical benefit coverage of on-demand treatments
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Expected benefit of early treatment: guidelines
“Compared to delayed treatment, early treatment is associated with better outcomes, including faster symptom resolution, shorter episode duration, and greater efficacy, regardless of the severity of the attack.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ODT, regardless of HAE endotype, reduces the risks of asphyxiation, abdominal symptoms, and functional impairment of the limbs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Core outcome set for acute treatment trials
“In the second round, a consensus of 90% or greater was achieved on a core outcome set consisting of five key outcomes: change in overall symptom severity at one predetermined time point between 15 minutes and 4 hours after treatment, time to end of progression of all symptoms, the need for rescue medication during the entire attack, impairment of daily activities, and treatment satisfaction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Attack duration with and without on-demand treatment: prospective cohorts
“Both icatibant and pdC1-INH significantly reduced attack duration compared with no treatment (median times from onset 7, 10 and 47 hours, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median attack duration (data available for 2393 attacks) with approved therapies was 10 h, significantly shorter than without treatment (45 h) or with tranexamic acid (38 h).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median time from onset of symptoms to drug administration was 1 h with icatibant and 2 h with pd-C1INH and median time from drug administration to complete resolution was 5.5 and 8 h, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time to symptom relief and resolution with oral sebetralstat: phase 3 trial
“The time to the beginning of symptom relief with the 300-mg dose and the 600-mg dose was faster than with placebo (P<0.001 and P = 0.001 for the two comparisons, respectively), with median times of 1.61 hours (interquartile range, 0.78 to 7.04), 1.79 hours (1.02 to 3.79), and 6.72 hours (1.34 to >12), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose, 49.5% with the 600-mg dose, and 27.4% with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time to symptom relief with oral sebetralstat during long-term prophylaxis: open-label extension
“Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deucrictibant outcomes in relation to other on-demand agents: RAPIDe-3 discussion
Reduced emergency department use with self-administration and on-demand access
“Data suggest that self-administration of icatibant reduces and delays the need for Emergency Department visits, which are typically required when attacks affect critical anatomical sites.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Burden of disease showed significant improvement in all domains except worry about children inheriting HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, our study shows that a substantial burden of illness remains for HAE patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes after delayed treatment: patient surveys
“Time to treatment paralleled changes in attack severity (33% mild attacks treated in <1 hour vs 67% in ≥1 hour, progressed to moderate/severe) and mean duration (<1 hour: 0.7 day; >8 hours: 2.7 days).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When asked how long it usually takes to feel in control of their HAE attacks after on-demand treatment, respondents reported a mean time of 2.2 h (SD: 5.1) post-treatment, with those who treat early (less than 1 h) reporting 1.4 h (SD: 1.1) and those who delay on-demand treatment reporting 2.9 h (SD: 6.7) (Fig. 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote